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ABSTRACT
Objective To summarise available evidence on diagnostic
tests that might help primary care physicians to identify
patients with an increased risk for colorectal cancer
among those consulting for non-acute lower abdominal
symptoms.
Data sources PubMed, Embase, and reference screening.
Study eligibility criteria Studies were selected if the
design was a diagnostic study; the patients were adults
consulting because of non-acute lower abdominal
symptoms; tests included signs, symptoms, blood tests,
or faecal tests.
Study appraisal and synthesis methods Two reviewers
independently assessed quality with a modified version
of the QUADAS tool and extracted data. We present
diagnostic two by two tables and pooled estimates of
sensitivity and specificity. We refrained from pooling
when there was considerable clinical or statistical
heterogeneity.
Results 47 primary diagnostic studies were included.
Sensitivity was consistently high for age ≥50 (range 0.81-
0.96,median 0.91), a referral guideline (0.80-0.94, 0.92),
and immunochemical faeces tests (0.70-1.00, 0.95). Of
these, only specificity of the faeces tests was good.
Specificity was consistently high for family history (0.75-
0.98, 0.91), weight loss (0.72-0.96, 0.89), and iron
deficiency anaemia (0.83-0.95, 0.92), but all tests lacked
sensitivity. None of these six tests was (sufficiently)
studied in primary care.
Conclusions Although combinations of symptom and
results of immunochemical faeces tests showed good
diagnostic performance for colorectal cancer, evidence
from primary care is lacking. High quality studies on their
role in the diagnostic investigation of colorectal cancer in
primary care are urgently needed.
INTRODUCTION
Colorectal cancer is the second most common cancer
in Europe.1 2 The five year survival rate for early stage
colorectal cancer is greater than 90%, whereas the five
year survival rate for those diagnosed with widespread
cancer is less than 10%.23 Early diagnosis is therefore of
utmost importance. As patients with abdominal symp-
toms usually present to primary care,4 it is important
that general practitioners can identify those at
increased risk. This is not straightforward as abdom-
inal symptoms are common in general practice,5 but
each year a general practitioner would probably
encounter no more than one new patient with color-
ectal cancer.6
Diagnostic tests couldhelpgeneral practitioners in the
diagnostic process. To be of value in primary care, diag-
nostic tests should be directly accessible to general prac-
titioners and their diagnostic accuracy should have been
demonstrated in this setting. These include the signs and
symptoms found with medical history and physical
examination, blood tests, and faecal occult blood tests.
Several guidelines have beendeveloped to assist general
practitioners in the diagnostic process. For example, in
2000 the Department of Health of England and Wales
introduced guidelines so that all patients with suspected
colorectal cancer couldbe seenbya specialistwithin two
weeks of referral (TWR guideline, see appendix A on
bmj.com).7 This referral guideline, however, has been
criticised for using symptoms that are so common
among the general practice population (such as change
in bowel habits) that many referrals can falsely be classi-
fied as high risk.8 Although the evidence for6 and com-
pliance with9 this guideline has already been reviewed,
as has its effect on colorectal services,10 a meta-analysis
of the diagnostic performance of the guideline itself is
lacking.Other researchers advocate faecal blood testing
in patients with symptoms as a guide to the urgency of
investigation.1112 Guaiac based tests are inexpensive but
sensitive to diet and medication, and immunochemical
based tests react only to human haemoglobin13 but are
more expensive ($15 (€11) v $22 (€16), respectively14).
In our hospital costs are around €11.80 (£10.60) and
€18.00 (£16.20), respectively.
The challenge in primary care is to find a sensitive
test that does not result in too many false positives.15
We summarised all the available evidence on the
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diagnostic performance of age, family history, weight
loss, individual signs and symptoms; combinations of
symptoms, referral guidelines; blood tests (such as for
anaemia); and faecal occult blood tests in diagnosing
colorectal cancer in adult patients with symptoms.
METHODS
Data sources and searches
We searched PubMed and Embase for eligible diag-
nostic studies (all publications to September 2008).
The search strategy used MeSH/EMTREE terms and
free textwords, and included subsearches related to the
study population, index test, target condition, and pub-
lication type. We added a methodological filter to
increase the specificity of the search. This sensitive fil-
ter was created by combining three filters for the iden-
tification of diagnostic studies via the Boolean operator
“OR”.16-18
Reference lists of all retrieved primary diagnostic
studies were checked for additional relevant diagnostic
studies. Additionally, we checked references of rele-
vant reviews, meta-analyses, guidelines, and commen-
taries identified in PubMed and Embase.
Study selection
Two authors (PJ, DvdW) independently applied the
predefined selection criteria. PJ checked all citations
(titles and abstracts) identified by the search strategy,
whileDvdWchecked eligibility of all citations assessed
by PJ as (possibly) relevant. Consensus meetings were
organised to discuss any disagreement regarding selec-
tion. Full publications were retrieved for studies that
seemed relevant, and for those for which relevance
was still unclear. A third review author (DB) was con-
sulted in cases of persisting disagreement.
Participants, setting, and study design
We considered studies eligible if the study population
consisted of adult patients consulting a physician with
non-acute lower abdominal symptoms. Therefore,
population based or screening studies—that is, studies
that include people without abdominal symptoms—
were excluded. We defined “non-acute” as being pre-
sent for at least two weeks.19 Although primary care is
the setting of interest, in some countries primary care is
notwell defined. Therefore, we decided to additionally
include studies performed at the interface between pri-
mary and secondary care, such as two week referral
clinics and open access outpatient clinics. In open
access clinics, patients’ characteristics and the spec-
trum of diseasemight resemble those found in primary
care populations. As not all publications clearly
reported whether or not an outpatient clinic was
directly accessible to patients, however, we decided
to select only those secondary care studies with a pre-
valence of colorectal cancer of less than 15%. By using
this criterion, which was the highest prevalence
reported in the primary care studies, we tried to mini-
mise the risk of bias from diagnostic pre-selection. Stu-
dies with hospital inpatients were also excluded.
Table 1 | Results of risk of bias assessment per study according to items on checklist for the
quality assessment of diagnostic accuracy studies20*
1 2 3 4 5 6 7 8 9 10 11
Bafandeh 2008† + + + + + + + ? ? + +
Barwick 2004 ? + ? + − − − − + + ?
Bjerregaard 2007 + + + + ? − − − ? + +
Bellentani 1990 + + + + − + − ? ? + ?
Brewster 1994 ? + + + − + + ? ? + −
Castiglione 1987 + + + + − − − ? ? − +
Charalambopoulos 2000 ? ? + ? + + + ? + + +
Chohan 2005 ? ? ? ? ? ? ? − + + +
Debnath 2002 ? + ? + ? ? ? − + + ?
Eccersley 2003 ? + + − − + − ? + + +
Ellis 2005 + ? + + + − − ? ? − +
Falkson 1993 ? + ? + + − − ? ? + +
Farrands 1985 ? ? + ? − + − ? ? + +
Flashman 2004 ? + ? + ? ? ? − ? + +
Fijten 1995 + ? ? + + − − ? ? + ?
Goulston 1980 ? + + ? − ? − ? ? + ?
Jeanson 1994 ? ? ? ? ? + + ? ? + +
Kimmig 1989 ? + + ? + + + ? ? + ?
Leicester 1983 ? ? + ? − − − ? ? + +
Levi 2007 ? ? + ? + + + + + ? ?
Mahon 2002 ? + + ? − − − ? ? + +
Mant 1989 + + + + − + − ? ? − ?
Marderstein 2008† + ? + + ? + + ? + + +
Metcalf 1996† + + + + + + + − + + +
Miyoshi 2000† ? + + + + + + + + + +
Niv 1995† − + + ? + + + − + + +
Norrelund 1996 + ? + + + − − ? ? + −
Panzuto 2003 + + + + − − − − + + −
Pepin 2002 ? − + − − − − − ? ? −
Pye 1989 ? ? + ? − + − ? ? + ?
Pye 1990 + ? + + − + − ? ? ? +
Robertson 2006 ? + + ? + ? ? − ? + ?
Selvachandran 2002 + + + + ? ? ? ? ? + +
Shastri 2008† ? + + + + + + + + + +
Sieg 1998† ? + + + ? + ? + + + +
Sieg 1999† ? + + + + + + + + + +
Smith 2006 ? + + + + + + − ? ? +
Steine 1994† ? + + + − + + + + + +
Tan 2002† + + + + + + + ? + + ?
Tate 1988 ? + + ? + + + ? + + ?
Tate 1989 + ? + ? − + − ? ? − +
Tate 1990 ? + + ? − + + + ? + +
Thomas 1992 ? + + ? − + − ? ? + +
Thompson 2007† + ? + + + + − ? + + +
Thompson 2008† + ? + + + + − ? + + +
Wauters 2000 + + + − + ? − ? ? ? +
Zarchy 1991 ? + + + − + + ? ? + ?
Total 18 30 40 28 20 29 18 7 19 38 30
+=no bias; −=potential bias; ?=bias unclear.
*1=valid selection, representative patients, 2=blinded to reference standard, 3=index test not part of reference
standard, 4=clinical data available as normal, 5=adequate reference test, 6=all/random selection received
reference test, 7=all received same test, 8= blinded to index test, 9=target condition did not change between tests,
10=no withdrawal, 11=no missing/uninterpretable data (see appendix B on bmj.com for full details of scoring).
†Study received positive assessment on at least eight of 11 quality items.
RESEARCH
page 2 of 21 BMJ | ONLINE FIRST | bmj.com
We included primary diagnostic studies with a
cohort design and case-control designs in which con-
trols formed a representative sample of all patientswith
abdominal symptoms. We excluded studies for which
we could not extract or reconstruct two by two tables,
studieswritten in a languageother thanEnglish,Dutch,
German, or French, and reviews, editorials, and case
reports.
Reference test
We included studies that used colonoscopy, barium
enema, or clinical follow-up as reference standards to
diagnose or exclude colorectal cancer. Studies that
used sigmoidoscopy as the single reference test were
excluded.
Index test
We included studies on tests that can be carried out or
are usually accessible in primary care, specifically age,
family history, weight loss, individual signs and symp-
toms; combinations of symptoms, including referral
guidelines; blood tests; and faecal occult blood tests.
Studies reporting data only on main indications for
colonoscopywere excludedas they ignore thepresence
of additional symptoms. As ultrasonography is not
commonly used in primary care we excluded this test.
Data collection and quality assessment
The reviewers extracted data on setting and design,
study population, test characteristics, and test results.
Methodological quality was assessed with a modified
version of the quality assessment of diagnostic
accuracy studies (QUADAS) tool,20 which is recom-
mended by the Cochrane Diagnostic Reviewers’
Handbook.21 This modified version consists of 11
items on methodological characteristics that have the
potential to introduce bias (see appendix B on
bmj.com). Items were scored as positive (no bias),
negative (potential bias), or unclear.
Two reviewers assessed eachpaper: PJ extracteddata
from all studieswhileHdV,DvdW, andDBeach extra-
cted data from a third of the studies, independently
from each other and using a standardised form. Agree-
ment between observers was quantified and disagree-
ments were resolved by consensus meetings.
As recommended by the designers of the QUADAS
toolwedid not applyweights to theQUADAS items or
use a summary score in the analysis. Instead, we used
subgroup analyses to explore whether scores on the
following quality items explained variation in diagnos-
tic performance: item 1 (validity of study sample), item
2 (test review bias), item 5 (validity of reference stan-
dard), and item 7 (differential verification bias). These
items have been shown to result in biased estimates of
diagnostic performance in empirical studies.22 23
Data synthesis and statistical analysis
We examined diagnostic two by two tables and diag-
nostic performance measures per study (sensitivity,
specificity, predictive values). We also looked at
study results by setting.
Positive predictive values (PPV) and the reverse of
negative predictive values (1−NPV), represent the
probability of colorectal cancer in patients with a posi-
tive or negative test result, respectively. These mea-
sures provide a clear indication of the diagnostic
value of a test—that is, the extent to which the prior
probability of colorectal cancer is modified by either
a positive or a negative test result. To illustrate results
of relevant diagnostic tests we present forest plots of
PPV and 1−NPV.
We used MetaDiSc statistical software to calculate
diagnostic performance measures and corresponding
95% confidence intervals.13 24 When four or more stu-
dies on a specific index test showed sufficient clinical
and statistical homogeneity, we used bivariate
analyses25 to calculate pooled estimates and 95% con-
fidence intervals for the summary estimates of sensitiv-
ity and specificity, and of positive and negative
predictive values. The bivariate analyses take into
account variability within and between studies and
the dependency between either sensitivity and specifi-
city or positive and negative predictive values. Bivari-
ate analyses based on a random effect model perform
better than SROC regression models derived with the
Moses and Littenberg method, which departs from a
fixed effects model.26 We defined statistical heteroge-
neity as non-overlapping confidence intervals for esti-
mates of diagnostic parameters and a difference in
these estimates among the studies of more than 20%.
When assessing heterogeneity we always simulta-
neously considered sensitivity and specificity (or PPV
and 1−NPV). In case of statistical or considerable
Citations identified by PubMed/Embase search strategy (n=3237):
  PubMed (n=1934)
  Embase (n=1303)
  In both databases (n=378)
Relevant papers identified in PubMed/Embase (n=38):
  Studies in both PubMed and Embase (n=18)
  Studies in PubMed only (n=15)
  Studies in Embase only (n=5)
Primary diagnostic studies included in the review (n=47)
  2 of 43 papers identified in PubMed/Embase reported on same study
  1 paper identified by checking references in study already identified on PubMed/Embase
References assessed by second reviewer as relevant or maybe relevant (n=421) 
Papers excluded after assessment (n=383):
  No relevant study population (n=219)
  No relevant study design or publication type (n=72)
  No relevant index test (n=41)
  No relevant reference test (n=9)
  No relevant target disease (n=19)
  Publication could not be retrieved (n=3); excluded languages (n=20)
Citations (title, abstract) screened by second reviewer (n=578)  
All references assessed by first reviewer as relevant or maybe relevant
Citations (title, abstract) screened by first reviewer (n=2859)
Relevant papers identified by reference checking (n=11)
Fig 1 | Results of search strategy and selection procedure
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Table 2 | Summary of findings (sensitivity, specificity, predictive values) for tests studied by at least four primary diagnostic studies, with medians in case of
heterogeneity and pooled estimates (95% confidence intervals) in case of homogeneity
Index test
and setting
No of
studies
Sensitivity Specificity Postitve test result Negative test result
Range Median/pooled Range Median/pooled Risk Median/pooled Risk Median/pooled
Non-gastrointestinal risk factors, individual signs and symptoms
Age >50 v <50
Primary care 2 0.86-0.96
0.91
0.39-0.46
0.36
0.06-0.11
0.10 (0.07 to 0.13)
0.01-0.01
0.02 (0.01 to 0.03)
Secondary care 4 0.81-0.96 0.30-0.66 0.08-0.19 0.01-0.07
Age >60 v <60
Primary care 3 0.73-0.93
0.83
0.52-0.88
0.55
0.05-0.20
0.09 (0.08 to 0.10)
0.00-0.02
0.02 (0.01 to 0.02)
Secondary care 4 0.50-0.85 0.48-0.84 0.08-0.10 0.02-0.03
Age >70 v <70
Primary care 3 0.36-0.63
0.50
0.72-0.83
0.79
0.08-0.31
0.13
0.03-0.08
0.03
Secondary care 1 0.25 0.94 0.12 0.03
Sex: male v female
Primary care 4 0.44-0.78
0.62
0.46-0.57
0.55
0.05-0.17
0.07 (0.05 to 0.12)
0.01-0.13
0.04 (0.02 to 0.07)TWR clinic 1 0.71 0.61 0.16 0.05
Secondary care 4 0.37-0.70 0.52-0.57 0.01-0.16 0.02-0.08
Family history
Primary care 2 0.00-0.13
0.16
0.86-0.91
0.91
0.00-0.10
0.06
0.09-0.11
0.04
Secondary care 4 0.00-1.00 0.75-0.98 0.00-0.13 0.00-0.05
Weight loss
Primary care 6 0.13-0.44
0.20
0.85-0.94
0.89
0.05-0.23
0.09
0.02-0.13
0.06TWR clinic 1 0.14 0.72 0.05 0.11
Secondary care 6 0.15-0.37 0.79-0.96 0.05-0.36 0.01-0.11
Palpable mass*
Primary care 2 0.11-0.22
—
0.89-0.96
—
0.04-0.32
—
0.04-0.06
—TWR clinic 2 0.06-0.25 0.94-0.99 0.16-0.80 0.08-0.13
Secondary care 1 0.04 0.97 0.08 0.06
Abdominal pain
Primary care 6 0.00-0.40
0.35
0.49-0.91
0.59
0.00-0.23
0.05
0.05-0.12
0.07TWR clinic 1 0.21 0.57 0.05 0.13
Secondary care 13 0.00-0.73 0.19-0.84 0.00-0.15 0.01-0.21
Rectal bleeding
Secondary care 13 0.25-0.86 0.44 0.31-0.88 0.66 0.03-0.21 0.07 (0.05 to 0.10) 0.01-0.14 0.04 (0.03 to 0.06)
All bleeding, dark blood
Primary care 4 0.25-0.41
0.35
0.69-0.87
0.85
0.07-0.17
0.14 (0.09 to 0.21)
0.03-0.10
0.05 (0.03 to 0.07)
Secondary care 1 0.35 0.90 0.20 0.05
All bleeding, mixed with stool
Primary care 4 0.09-0.77 0.51 0.49-0.95 0.71 0.03-0.14 0.06 (0.04 to 0.10) 0.01-0.06 0.03 (0.01 to 0.05)
Change in bowel habit present v absent
Primary care 6 0.10-1.00
0.52
0.55-0.93
0.61
0.05-0.50
0.09
0.00-0.39
0.04
Secondary care 12 0.06-0.86 0.28-0.94 0.03-0.27 0.02-0.15
Diarrhoea present v absent
Primary care 1 0.25
0.20 (0.14 to 0.29)
0.73
0.73 (0.67 to 0.78)
0.07
0.06 (0.02 to 0.15)
0.08
0.10 (0.07 to 0.14)
Secondary care 4† 0.06-0.24 0.65-0.79 0.01-0.14 0.05-0.16
Constipation
Primary care 1 0.13
0.13
0.58
0.72
0.03
0.06 (0.02 to 0.18)
0.12
0.09 (0.05 to 0.15)
Secondary care 3 0.00-0.51 0.53-0.90 0.00-0.16 0.03-0.14
Peri-anal symptoms‡
Primary care 3 0.25-0.36
—
0.22-0.95
—
0.02-0.18
—
0.02-0.17
—
Secondary care 2 0.36-0.56 0.39-0.40 0.03-0.04 0.05-0.08
Symptom combinations, including referral guidelines
TWR guidelines positive v negative
TWR clinic 4 0.86-0.92
0.92
0.30-0.54
0.42
0.12-0.25
0.14
0.02-0.04
0.03
Secondary care 1§ 0.80-0.94 0.54-0.56 0.08-0.14 0.01-0.02
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clinical heterogeneity (in terms of characteristics of
populations or tests) we refrained from pooling and
presented median values and ranges instead.
Investigations of heterogeneity
Factors that can contribute to variation in diagnostic
performance across studies (heterogeneity) include dif-
ferences in (a) setting (primary care v primary-second-
ary care interface v secondary care); (b) prevalence of
CRC (<5% v ≥5%), (c) tumour location (rectum v other
left sided (sigmoid, colon descendens, flexura lienalis)
v right sided (rest)); (d) cancer type (Dukes’s A and B v
Dukes’s C andD); (e1) faecal occult blood tests (guaiac
v immunochemical); (e2) guaiac based faecal occult
blood tests (dietary restrictions v no restrictions); (e3):
guaiac based faecal occult blood tests (self test v regular
test); (f) QUADAS items 1, 2, 5, or 7 (as described
above). Subgroup analyses (a), (b), (e1), (e2), and (f)
concern analyses between study subgroups, while (c),
(d), (e1), and (e3) concern analyses within studies.
Subgroup analyses were performed only when each
subgroup included data of at least four diagnostic stu-
dies. In case of statistical homogeneous results for both
sensitivity and specificity per subgroup, we calculated
pooled estimates using bivariate analyses. In case of
statistical heterogeneous results, we presented the
rangeof sensitivity and specificityper subgroup. Studies
that provided insufficient information on a factor could
not be included in that specific subgroup analysis.
RESULTS
Literature search and study selection
The literature search yielded 2859 references. A total
of 421 full papers were retrieved, of which 38 were
finally considered relevant for the review.11 12 27-62
Reference checking yielded 11 additional relevant
papers.8 63-72 As four papers8 29 30 72 presented informa-
tion on two studies, our total number of primary diag-
nostic studies for inclusion was 47. Figure 1
summarises the search results.
Study characteristics
Full details of the 47 included studies are in appendixC
onbmj.com.All studieswere cohort studies onpatients
with abdominal symptoms. Nine studies took place in
primary care, with the prevalence of colorectal cancer
ranging from 3% to 15%.31 33 34 40 44 49 61 63 70 Signs and
symptoms were the main index tests in these studies.
Seven studies used rectal bleeding as the inclusion
criterion.33 34 40 44 49 61 70 Five studies were performed at
the interface between primary and secondary care,
with prevalence of colorectal cancer ranging from 9%
to14%.28 65-68 Three studies included individual referral
criteria as the index test28 65 68; four studies used the
referral guideline itself (that is, combination of
criteria).65-68 Of the 33 studies in secondary care, 20
were performed in diagnostic clinics
(colonoscopy,8 27 32 36 37 39 41 43 45 46 50-53 55 71 double con-
trast barium enema5457 62 64) and 13 in outpatient
clinics.11 12 29 35 38 42 47 48 56 58-60 69 Prevalence of colorectal
cancer ranged from 0.4% to 15%.
Quality assessment
On average, the reviewers disagreed in three out of 11
items (range 1-6 across studies). Table 1 presents the
results of the quality assessment after consensus.
Index test
and setting
No of
studies
Sensitivity Specificity Postitve test result Negative test result
Range Median/pooled Range Median/pooled Risk Median/pooled Risk Median/pooled
Blood tests
Positive v negative result on test for iron deficiency anaemia
TWR clinic 2 0.09-0.20
0.13
0.92-0.94
0.92
0.11-0.34
0.13
0.09-0.12
0.08
Secondary care 6 0.07-0.68 0.83-0.95 0.04-0.41 0.01-0.11
Faecal occult blood tests
Positive v negative result on guaiac based tests
Primary care 1¶ 0.57
0.75
0.90
0.86
0.18
0.28
0.02
0.01
Secondary care 13 0.33-1.00 0.72-0.94 0.07-0.59 0.00-0.07
Positive v negative result on immunological based tests
Secondary care 8 0.70-1.00 0.95 0.71-0.93 0.84 0.07-0.59 0.21 0.00-0.05 0.00
TWR=two week referral.
*Summary of findings not presented as some studies included rectal mass as index test while others included abdominal mass.
†Excludes study of Pepin et al because of inclusion criterion “constipation.”
‡Summary of findings not presented as studies included different types of peri-anal symptoms (for example, anal itch, haemorrhoids).
§Excludes study by Selvachandran et al because they used abridged version of two week referral TWR guideline;
¶Excludes study by Fijten et al because of inclusion criterion “rectal bleeding.”
Primary care
Robertson 2006
Wauters 2000
Secondary care
Bafandeh 2008
Panzuto 2003
Tan 2002
Thompson 2007
Pooled estimate
0 0.1 0.2 0.3
Positive predictive value (PPV)
0 0.1 0.2 0.3
1–negative predictive value (1–NPV)
Fig 2 | Risk of colorectal cancer in patients aged ≥50 (positive predictive value) versus risk in
patients <50 (1−negative predictive value)
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Potential sources of biasmost frequently identified con-
cerned an invalid reference standard (item5) anddiffer-
ential verification bias (item 7). Valid selection and
representativeness of study populations (item 1), blind
interpretation of results of the reference standard (item
8), and length of the period between index test and
reference standard (item 9) were poorly described
(that is, score unclear). Generally, 12 studies performed
well, receiving a positive assessment of at least eight out
of 11 QUADAS items.2741-43 50-52 54 55 596070
Table 3 | Diagnostic performance of age and sex in diagnosis of colorectal cancer
Index test and setting TP FP FN TN
Sensitivity
(95% CI)
Specificity
(95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Age
≥50 v <50, all bleeding, primary care
Robertson 2006 19 315 3 267 0.86 (0.65 to 0.97) 0.46 (0.42 to 0.50) 0.06 (0.04 to 0.09) 0.01 (0.00 to 0.03)
Wauters 2000 26 219 1 140 0.96 (0.81 to 1.00) 0.39 (0.34 to 0.44) 0.11 (0.07 to 0.15) 0.01 (0.00 to 0.04)
≥60 v <60, all bleeding, primary care
Ellis 2005 8 147 3 161 0.73 (0.39 to 0.94) 0.52 (0.47 to 0.58) 0.05 (0.02 to 0.10) 0.02 (0.00 to 0.05)
Fijten 1995 8 32 1 228 0.89 (0.52 to 1.00) 0.88 (0.83 to 0.91) 0.20 (0.09 to 0.36) 0.00 (0.00 to 0.02)
Wauters 2000 25 163 2 196 0.93 (0.76 to 0.99) 0.55 (0.49 to 0.60) 0.13 (0.09 to 0.19) 0.01 (0.00 to 0.04)
≥70 v <70, all bleeding, primary care
Robertson 2006 8 99 14 483 0.36 (0.17 to 0.59) 0.83 (0.80 to 0.86) 0.08 (0.03 to 0.14) 0.03 (0.02 to 0.05)
Wauters 2000 17 100 10 259 0.63 (0.42 to 0.81) 0.72 (0.67 to 0.77) 0.15 (0.09 to 0.22) 0.04 (0.02 to 0.07)
Norrelund 1996 34 76 20 234 0.63 (0.49 to 0.76) 0.76 (0.70 to 0.80) 0.31 (0.22 to 0.40) 0.08 (0.05 to 0.12)
≥80 v <80, all bleeding, primary care
Wauters 2000 3 48 24 311 0.11 (0.02 to 0.29) 0.87 (0.83 to 0.90) 0.06 (0.01 to 0.16) 0.07 (0.05 to 0.11)
≥40 v <40, secondary care
Selvachandran 2002 93 1809 2 364 0.98 (0.93 to 1.00) 0.17 (0.15 to 0.18) 0.05 (0.04 to 0.06) 0.01 (0.00 to 0.02)
Thompson 2007 462 6736 5 1326 0.99 (0.98 to 0.99) 0.16 (0.16 to 0.17) 0.06 (0.06 to 0.07) 0.00 (0.00 to 0.01)
≥50 v <50, secondary care
Bafandeh 2008 14 156 2 308 0.88 (0.62 to 0.98) 0.66 (0.62 to 0.71) 0.08 (0.05 to 0.13) 0.01 (0.00 to 0.02)
Panzuto 2003 39 168 2 71 0.95 (0.84 to 0.99) 0.30 (0.24 to 0.36) 0.19 (0.14 to 0.25) 0.03 (0.00 to 0.10)
Tan 2002 47 286 11 141 0.81 (0.69 to 0.90) 0.33 (0.29 to 0.38) 0.14 (0.11 to 0.18) 0.07 (0.04 to 0.13)
Thompson 2007 449 5497 18 2565 0.96 (0.94 to 0.98) 0.32 (0.31 to 0.33) 0.08 (0.07 to 0.08) 0.01 (0.00 to 0.01)
≥60 v <60, secondary care
Bafandeh 2008 8 74 8 390 0.50 (0.25 to 0.75) 0.84 (0.80 to 0.87) 0.10 (0.04 to 0.18) 0.02 (0.01 to 0.04)
Bjerregaard 2007 90 1076 32 974 0.74 (0.65 to 0.81) 0.48 (0.45 to 0.50) 0.09 (0.06 to 0.09) 0.03 (0.02 to 0.05)
Selvachandran 2002* 130 1425 26 1721 0.83 (0.77 to 0.89) 0.55 (0.53 to 0.57) 0.08 (0.07 to 0.10) 0.02 (0.01 to 0.02)
Thompson 2007 396 4017 71 4045 0.85 (0.81 to 0.88) 0.50 (0.49 to 0.51) 0.09 (0.08 to 0.10) 0.02 (0.01 to 0.02)
≥65 v <65, secondary care
Zarchy 1991 13 255 10 516 0.57 (0.35 to 0.77) 0.67 (0.64 to 0.70) 0.05 (0.03 to 0.08) 0.02 (0.01 to 0.04)
≥70 v <70, secondary care
Bafandeh 2008 4 30 12 434 0.25 (0.07 to 0.52) 0.94 (0.91 to 0.96) 0.12 (0.03 to 0.28) 0.03 (0.01 to 0.05)
≥80 v <80, secondary care
Thompson 2007 100 715 367 7347 0.21 (0.18 to 0.25) 0.91 (0.91 to 0.92) 0.12 (0.10 to 0.15) 0.05 (0.04 to 0.05)
Sex male v female
All bleeding, primary care
Fijten 1995 7 111 2 149 0.78 (0.40 to 0.97) 0.57 (0.51 to 0.63) 0.06 (0.02 to 0.12) 0.01 (0.00 to 0.05)
Mant 1989 7 70 9 59 0.44 (0.20 to 0.70) 0.46 (0.37 to 0.55) 0.09 (0.04 to 0.18) 0.13 (0.06 to 0.24)
Norrelund 1996 29 139 25 171 0.54 (0.40 to 0.67) 0.55 (0.49 to 0.61) 0.17 (0.12 to 0.24) 0.13 (0.08 to 0.18)
Robertson 2006 13 260 9 322 0.59 (0.36 to 0.79) 0.55 (0.51 to 0.59) 0.05 (0.03 to 0.08) 0.03 (0.01 to 0.05)
Two week referral clinic
Barwick 2004 10 51 4 79 0.71 (0.42 to 0.92) 0.61 (0.52 to 0.69) 0.16 (0.08 to 0.28) 0.05 (0.01 to 0.12)
Secondary care
Selvachandran 2002* 98 1421 58 1725 0.63 (0.55 to 0.70) 0.55 (0.53 to 0.57) 0.07 (0.05 to 0.08) 0.03 (0.02 to 0.04)
Tan 2002 36 185 22 242 0.62 (0.48 to 0.74) 0.57 (0.52 to 0.61) 0.16 (0.12 to 0.22) 0.08 (0.05 to 0.12)
Zarchy 1991 16 363 7 408 0.70 (0.47 to 0.87) 0.53 (0.49 to 0.56) 0.04 (0.02 to 0.07) 0.02 (0.01 to 0.03)
All constipated, secondary care
Pepin 2002 3 267 5 288 0.37 (0.08 to 0.75) 0.52 (0.48 to 0.56) 0.01 (0.00 to 0.03) 0.02 (0.01 to 0.04)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
*For this study we extracted data for some index tests from more recent paper of Hodder et al.72
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Diagnostic performance of individual characteristics
Table 2 summarises the findings, including the results
of tests that have been studied by at least four primary
diagnostic studies.
Age, sex, family history, and weight loss
Results for age and sex are summarised in table 3 and
for family history and weight loss in table 4. For age,
sensitivity and specificity were strongly dependent on
the cut-off value; the lower the cut-off score (such as age
≥40), the higher sensitivity and the lower
specificity. 8 27 29 33 34 44 45 49 55 59 61 62 Figure 2 shows the
PPV and 1−NPV using a cut-off of ≥50 for age. Pooled
estimates (six studies) showed that patients aged ≥50
had a 10% risk of colorectal cancer (95% confidence
interval 7% to 13%), while patients aged <50 had a
risk of 2% (1% to 3%). There is a sharp decrease in
sensitivity with a cut-off for age of ≥70 compared with
a cut-off of age ≥60 (median 0.50 and 0.83, respec-
tively) (table 2). For sex (male) sensitivity ranged
from 0.37 to 0.78, while specificity ranged from 0.46
to 0.57 (table 3). 8 28 34 40 44 46 49 55 62 The risk for colorectal
cancer inmen is somewhat higher than inwomen (0.07
v 0.04), but confidence intervals overlap (table 2). For
family history (present) 27 27 29 29 32 32 40 46 46 62 70 and
weight loss (present) 8 2829 34 40 44-46 49 54 61 62 70 specificity
seemed to be rather consistent and high (medians
0.91 and 0.89, respectively) (tables 2 and 4). Sensitiv-
ity, however, ranged from 0.00 to 1.00 for family his-
tory and from 0.13 to 0.44 for weight loss. For all four
factors visual inspection showed no differences
between the different settings of care.
Signs
Five studies reported on the diagnostic performance of
a palpable mass (table 5). 29 34 61 65 68 Sensitivity ranged
from 0.04 (abdominal tumour) to 0.25 (rectal mass),
while specificity ranged from 0.89 to 0.99 (rectal
mass). In the study of Flashman et al general practi-
tioners identified in the same cohort of patients many
Table 4 | Diagnostic performance of family history and weight loss in diagnosis of colorectal cancer
Index test and setting TP FP FN TN
Sensitivity
(95% CI)
Specificity
(95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Family history
All bleeding, 1st degree relative with colorectal cancer, primary care
Mant 1989 2 18 14 109 0.13 (0.02 to 0.38) 0.86 (0.79 to 0.91) 0.10 (0.01 to 0.32) 0.11 (0.06 to 0.18)
Family history, primary care
Metcalf 1996 0 8 8 83 0.00 (0.00 to 0.37) 0.91 (0.83 to 0.96) 0.00 (0.00 to 0.37) 0.09 (0.04 to 0.17)
Family history of cancer, secondary care
Bafandeh 2008 0 10 16 454 0.00 (0.00 to 0.21) 0.98 (0.96 to 0.99) 0.00 (0.00 to 0.31) 0.03 (0.02 to 0.06)
1st degree relative >50 with colorectal cancer, secondary care
Bjerregaard 2007 23 183 99 1867 0.19 (0.12 to 0.27) 0.91 (0.90 to 0.92) 0.11 (0.07 to 0.16) 0.05 (0.04 to 0.06)
One or two 1st degree relatives with colorectal cancer, secondary care
Charalambopoulos2000 3 200 0 592 1.00 (0.29 to 1.00) 0.75 (0.72 to 0.78) 0.02 (0.00 to 0.04) 0.00 (0.00 to 0.01)
All constipated, family history, secondary care
Pepin 2002 2 14 6 541 0.25 (0.03 to 0.65) 0.98 (0.96 to 0.99) 0.13 (0.02 to 0.38) 0.01 (0.00 to 0.02)
Weight loss
All bleeding, primary care
Fijten 1995 4 38 5 222 0.44 (0.14 to 0.79) 0.85 (0.81 to 0.89) 0.10 (0.03 to 0.23) 0.02 (0.01 to 0.05)
Mant 1989 2 12 14 115 0.13 (0.02 to 0.38) 0.91 (0.84 to 0.95) 0.14 (0.02 to 0.43) 0.11 (0.06 to 0.18)
Metcalf 1996 2 13 6 78 0.25 (0.03 to 0.65) 0.86 (0.77 to 0.92) 0.13 (0.02 to 0.41) 0.07 (0.03 to 0.15)
Norrelund 1996 10 34 40 266 0.20 (0.10 to 0.34) 0.89 (0.85 to 0.92) 0.23 (0.12 to 0.38) 0.13 (0.10 to 0.17)
Robertson 2006 3 59 19 512 0.14 (0.03 to 0.35) 0.90 (0.87 to 0.92) 0.05 (0.01 to 0.14) 0.04 (0.02 to 0.06)
Wauters 2000 4 21 23 338 0.15 (0.04 to 0.34) 0.94 (0.91 to 0.96) 0.16 (0.05 to 0.36) 0.06 (0.04 to 0.09)
Two week referral clinic
Barwick 2004 2 36 12 94 0.14 (0.02 to 0.43) 0.72 (0.64 to 0.80) 0.05 (0.01 to 0.18) 0.11 (0.06 to 0.19)
Secondary care
Selvachandran 2002 17 163 78 2010 0.18 (0.11 to 0.27) 0.93 (0.91 to 0.94) 0.09 (0.06 to 0.15) 0.04 (0.03 to 0.05)
Steine 1994 17 335 38 1450 0.31 (0.19 to 0.45) 0.81 (0.79 to 0.83) 0.05 (0.03 to 0.08) 0.03 (0.02 to 0.04)
Zarchy 1991 4 52 19 719 0.17 (0.05 to 0.39) 0.93 (0.91 to 0.95) 0.07 (0.02 to 0.17) 0.03 (0.02 to 0.04)
Bjerregaard 2007 26 426 96 1624 0.21 (0.14 to 0.30) 0.79 (0.77 to 0.81) 0.06 (0.04 to 0.08) 0.06 (0.05 to 0.07)
Loss >3 kg in past 3 months, secondary care
Panzuto 2003 15 27 26 212 0.37 (0.22 to 0.53) 0.89 (0.84 to 0.92) 0.36 (0.22 to 0.52) 0.11 (0.07 to 0.16)
Loss ≥3 kg, secondary care
Bjerregaard 2007 18 321 104 1729 0.15 (0.09 to 0.22) 0.84 (0.83 to 0.86) 0.05 (0.03 to 0.08) 0.06 (0.05 to 0.07)
Pepin 2002 2 25 6 530 0.25 (0.03 to 0.65) 0.96 (0.93 to 0.97) 0.07 (0.01 to 0.24) 0.01 (0.00 to 0.02)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
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more palpable abdominal or rectal masses than
clinicians in the clinic (43 v 22 and 53 v 28,
respectively). 68 Of the 43 patients identified by the
general practitioner as having an abdominal mass,
seven (16%) were diagnosed with colorectal cancer
compared with four of the 22 (18%) identified in the
clinic. Of the 53 patients identified by the general prac-
titioner as having a rectal mass, 12 (23%) were diag-
nosed with colorectal cancer compared with 13 of 28
(46%) identified in the clinic.
Table 5 | Diagnostic performance of abdominal signs and symptoms in diagnosis of colorectal cancer
Index test and setting TP FP FN TN
Sensitivity
(95% CI)
Specificity
(95% CI)
Risk with positive test result
(95% CI)
Risk with negative
test result (95% CI)
Signs
All bleeding, palpable rectal mass, primary care
Fijten 1995 1 22 8 177 0.11 (0.00 to 0.48) 0.89 (0.84 to 0.93) 0.04 (0.00 to 0.22) 0.04 (0.02 to 0.08)
Wauters 2000 6 13 21 346 0.22 (0.09 to 0.42) 0.96 (0.94 to 0.98) 0.32 (0.13 to 0.57) 0.06 (0.04 to 0.09)
Abdominal mass*, two week referral clinic
Chohan 2005 7 10 57 388 0.11 (0.05 to 0.21) 0.98 (0.95 to 0.99) 0.41 (0.18 to 0.67) 0.13 (0.10 to 0.16)
Palpable abdominal mass*, right sided, two week referral clinic
Flashman 2004, GP findings 7 36 58 594 0.11 (0.04 to 0.21) 0.94 (0.92 to 0.96) 0.16 (0.07 to 0.31) 0.09 (0.07 to 0.11)
Flashman 2004, clinic
findings
4 18 61 612 0.06 (0.02 to 0.15) 0.97 (0.96 to 0.98) 0.18 (0.05 to 0.40) 0.09 (0.07 to 0.12)
Rectal mass*, two week referral clinic
Chohan 2005 16 4 48 394 0.25 (0.15 to 0.37) 0.99 (0.97 to 1.00) 0.80 (0.56 to 0.94) 0.11 (0.08 to 0.14)
Palpable rectal mass*, not pelvic, two week referral clinic
Flashman 2004, GP findings 12 41 53 589 0.19 (0.10 to 0.30) 0.94 (0.91 to 0.95) 0.23 (0.12 to 0.36) 0.08 (0.06 to 0.11)
Flashman 2004, clinic
findings
13 15 52 615 0.20 (0.11 to 0.32) 0.98 (0.96 to 0.99) 0.46 (0.28 to 0.66) 0.08 (0.06 to 0.10)
Abdominal tumour, secondary care
Bjerregaard 2007 5 56 117 1994 0.04 (0.01 to 0.09) 0.97 (0.97 to 0.98) 0.08 (0.03 to 0.18) 0.06 (0.05 to 0.07)
Abdominal pain
All bleeding, abdominal pain, primary care
Fijten 1995 3 132 6 128 0.33 (0.08 to 0.70) 0.49 (0.43 to 0.56) 0.02 (0.01 to 0.06) 0.05 (0.02 to 0.10)
Mant 1989 4 39 12 89 0.25 (0.07 to 0.52) 0.70 (0.61 to 0.77) 0.09 (0.03 to 0.22) 0.12 (0.06 to 0.20)
Metcalf 1996 3 39 5 52 0.38 (0.09 to 0.76) 0.57 (0.46 to 0.68) 0.07 (0.02 to 0.20) 0.09 (0.03 to 0.19)
Norrelund 1996 21 69 31 234 0.40 (0.27 to 0.55) 0.77 (0.72 to 0.82) 0.23 (0.15 to 0.33) 0.12 (0.08 to 0.16)
Robertson 2006 4 228 16 342 0.20 (0.06 to 0.44) 0.60 (0.56 to 0.64) 0.02 (0.00 to 0.04) 0.05 (0.03 to 0.07)
Wauters 2000 0 34 27 325 0.00 (0.00 to 0.13) 0.91 (0.87 to 0.93) 0.00 (0.00 to 0.10) 0.08 (0.05 to 0.11)
Abdominal pain, two week referral clinic
Barwick 2004 3 56 11 74 0.21 (0.05 to 0.51) 0.57 (0.48 to 0.66) 0.05 (0.01 to 0.14) 0.13 (0.07 to 0.22)
Abdominal pain, secondary care
Bafandeh 2008 7 140 9 324 0.44 (0.20 to 0.70) 0.70 (0.65 to 0.74) 0.05 (0.02 to 0.10) 0.03 (0.01 to 0.05)
Bjerregaard 2007 57 1116 65 934 0.47 (0.38 to 0.56) 0.46 (0.43 to 0.48) 0.05 (0.04 to 0.06) 0.07 (0.05 to 0.08)
Brewster 1994 0 81 21 360 0.00 (0.00 to 0.16) 0.82 (0.78 to 0.85) 0.00 (0.00 to 0.05) 0.06 (0.03 to 0.08)
Farrands 1995 2 85 11 41 0.15 (0.02 to 0.45) 0.33 (0.25 to 0.42) 0.02 (0.00 to 0.08) 0.21 (0.11 to 0.35)
Panzuto 2003 30 193 11 46 0.73 (0.57 to 0.86) 0.19 (0.14 to 0.25) 0.14 (0.09 to 0.19) 0.19 (0.10 to 0.32)
Selvachandran 2002 33 1196 62 977 0.35 (0.25 to 0.45) 0.45 (0.43 to 0.47) 0.03 (0.02 to 0.04) 0.06 (0.05 to 0.08)
Steine 1994 27 1269 28 508 0.49 (0.35 to 0.63) 0.29 (0.27 to 0.31) 0.02 (0.01 to 0.03) 0.05 (0.04 to 0.08)
Tan 2002 21 117 37 310 0.36 (0.24 to 0.50) 0.73 (0.68 to 0.77) 0.15 (0.10 to 0.22) 0.11 (0.08 to 0.14)
Tate 1988 3 43 11 73 0.21 (0.05 to 0.51) 0.63 (0.54 to 0.72) 0.07 (0.01 to 0.18) 0.13 (0.07 to 0.22)
Thompson 2007 206 3557 261 4505 0.44 (0.40 to 0.49) 0.56 (0.56 to 0.57) 0.06 (0.05 to 0.06) 0.06 (0.05 to 0.06)
Thompson 2008 311 7042 635 8445 0.33 (0.30 to 0.36) 0.55 (0.54 to 0.55) 0.04 (0.04 to 0.05) 0.07 (0.07 to 0.08)
Zarchy 1991 11 307 12 464 0.48 (0.27 to 0.69) 0.60 (0.57 to 0.64) 0.04 (0.02 to 0.06) 0.03 (0.01 to 0.04)
Abdominal pain as only symptom, secondary care
Thompson 2008 12 900 934 14 587 0.01 (0.01 to 0.02) 0.94 (0.94 to 0.95) 0.01 (0.01 to 0.02) 0.06 (0.06 to 0.06)
All constipated, abdominal pain, secondary care
Pepin 2002 4 89 4 466 0.50 (0.16 to 0.84) 0.84 (0.81 to 0.87) 0.04 (0.01 to 0.11) 0.01 (0.00 to 0.02)
All bleeding, spasms, primary care
Wauters 2000 6 105 21 254 0.22 (0.09 to 0.42) 0.71 (0.66 to 0.75) 0.05 (0.02 to 0.11) 0.08 (0.05 to 0.11)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
*Two week referral criterion.
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Symptoms
Individual symptoms most commonly investigated
included abdominal pain, rectal bleeding, (change in)
bowel habit, and peri-anal symptoms. For abdominal
pain (20 studies)8 12 27-29 34 40 44-46 49 54 55 59-62 64 70 71 test
results were heterogeneous with sensitivity ranging
from 0.00 to 0.73 and specificity from 0.19 to 0.91
(table 2). In four of the 13 secondary care studies
(table 5) the risk for colorectal cancer was significantly
lower among those with abdominal pain than among
those without. 8 12 54 60
Table 6 shows data on rectal bleeding (13
studies8 12 27 29 45 46 54 55 59 60 62 64 71). Sensitivity ranged
from 0.25 to 0.86, while specificity ranged from 0.31
to 0.88 (table 2). Comparing the risk for colorectal
cancer in those with a positive test result with those
with a negative test result shows that patients with rec-
tal bleeding, and also patients with blood mixed with
stool have a somewhat higher risk (pooled estimates
0.07 and 0.06, respectively) than those without (pooled
estimates 0.04 and 0.03, respectively) (table 2, fig 3).
Confidence intervals, however, overlap each other.
Patients with dark blood have a significantly higher
risk than those without dark blood (pooled estimates
0.14, 0.09 to 0.21, and 0.05, 0.03 to 0.07, respectively)
(table 2, fig 4).
Table 7 shows data on change in bowel habits (18
studies8 12 27 29 33 34 40 44 45 49 54 55 59 60 62 64 70 71). Results were
heterogeneous with sensitivity ranging from 0.06 to
1.00 and specificity from 0.28 to 0.94 (table 2). For
Table 6 | Diagnostic performance of rectal bleeding in diagnosis of colorectal cancer
Index test and setting TP FP FN TN
Sensitivity
(95% CI)
Specificity
(95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Rectal bleeding, secondary care
Bafandeh 2008 4 138 12 326 0.25 (0.07 to 0.52) 0.70 (0.66 to 0.74) 0.03 (0.01 to 0.07) 0.04 (0.02 to 0.06)
Bjerregaard 2007 83 1090 39 960 0.68 (0.59 to 0.76) 0.47 (0.45 to 0.49) 0.07 (0.06 to 0.09) 0.04 (0.03 to 0.05)
Brewster 1994 9 150 12 291 0.43 (0.22 to 0.66) 0.66 (0.61 to 0.70) 0.06 (0.03 to 0.11) 0.04 (0.02 to 0.07)
Farrands 1995 5 62 8 64 0.39 (0.14 to 0.68) 0.51 (0.42 to 0.60) 0.08 (0.03 to 0.17) 0.11 (0.05 to 0.21)
Panzuto 2003 18 96 23 143 0.44 (0.29 to 0.60) 0.60 (0.53 to 0.66) 0.16 (0.10 to 0.24) 0.14 (0.09 to 0.20)
Selvachandran 2002 82 1505 13 668 0.86 (0.78 to 0.93) 0.31 (0.29 to 0.33) 0.05 (0.04 to 0.06) 0.02 (0.01 to 0.03)
Steine 1994 17 271 37 1498 0.32 (0.20 to 0.46) 0.85 (0.83 to 0.86) 0.06 (0.04 to 0.09) 0.02 (0.02 to 0.03)
Tan 2002 33 121 25 306 0.57 (0.43 to 0.70) 0.72 (0.67 to 0.76) 0.21 (0.15 to 0.29) 0.08 (0.05 to 0.11)
Tate 1988 9 40 5 76 0.64 (0.35 to 0.87) 0.66 (0.56 to 0.74) 0.18 (0.09 to 0.32) 0.06 (0.02 to 0.14)
Thompson 2007 333 5079 134 2983 0.71 (0.67 to 0.75) 0.37 (0.36 to 0.38) 0.06 (0.06 to 0.07) 0.04 (0.04 to 0.05)
Thompson 2008 624 9841 322 5646 0.66 (0.63 to 0.69) 0.37 (0.36 to 0.37) 0.06 (0.06 to 0.06) 0.05 (0.05 to 0.06)
Zarchy 1991 8 222 15 549 0.35 (0.16 to 0.57) 0.71 (0.68 to 0.74) 0.04 (0.02 to 0.07) 0.03 (0.02 to 0.04)
Rectal bleeding as only symptom, secondary care
Thompson 2008 105 4128 841 11 359 0.11 (0.09 to 0.13) 0.73 (0.73 to 0.74) 0.02 (0.02 to 0.03) 0.07 (0.07 to 0.07)
All constipated, bleeding overt, secondary care
Pepin 2002 2 66 6 489 0.25 (0.03 to 0.65) 0.88 (0.85 to 0.91) 0.03 (0.00 to 0.10) 0.01 (0.00 to 0.03)
All bleeding, dark blood, primary care
Ellis 2005 3 28 8 191 0.27 (0.06 to 0.61) 0.87 (0.82 to 0.91) 0.10 (0.02 to 0.26) 0.04 (0.02 to 0.08)
Mant 1989 4 19 12 109 0.25 (0.07 to 0.52) 0.85 (0.78 to 0.91) 0.17 (0.05 to 0.39) 0.10 (0.05 to 0.17)
Metcalf 1996 3 28 5 63 0.38 (0.09 to 0.76) 0.69 (0.59 to 0.79) 0.10 (0.02 to 0.26) 0.07 (0.02 to 0.16)
Robertson 2006 9 112 13 470 0.41 (0.21 to 0.64) 0.81 (0.77 to 0.84) 0.07 (0.04 to 0.14) 0.03 (0.01 to 0.05)
All bleeding, dark blood, secondary care
Bjerregaard 2007 29 114 54 976 0.35 (0.25 to 0.46) 0.90 (0.88 to 0.91) 0.20 (0.14 to 0.28) 0.05 (0.04 to 0.07)
All bleeding, first episode, primary care
Ellis 2005 5 101 6 154 0.46 (0.17 to 0.77) 0.60 (0.54 to 0.66) 0.05 (0.02 to 0.11) 0.04 (0.01 to 0.08)
Fijten 1995 9 164 0 96 1.00 (0.66 to 1.00) 0.37 (0.31 to 0.43) 0.05 (0.02 to 0.10) 0.00 (0.00 to 0.04)
Norrelund 1996 45 271 9 39 0.83 (0.71 to 0.92) 0.13 (0.09 to 0.17) 0.14 (0.11 to 0.19) 0.19 (0.09 to 0.33)
All bleeding, mixed with stool, primary care
Ellis 2005 1 32 10 223 0.09 (0.00 to 0.41) 0.88 (0.83 to 0.91) 0.03 (0.00 to 0.16) 0.04 (0.02 to 0.08)
Metcalf 1996 5 41 3 50 0.63 (0.25 to 0.92) 0.55 (0.44 to 0.65) 0.11 (0.04 to 0.24) 0.06 (0.01 to 0.16)
Robertson 2006 17 297 5 285 0.77 (0.55 to 0.92) 0.49 (0.45 to 0.53) 0.05 (0.03 to 0.09) 0.02 (0.01 to 0.04)
All bleeding, solely mixed with stool, primary care
Fijten 1995 2 12 3 227 0.40 (0.05 to 0.85) 0.95 (0.91 to 0.97) 0.14 (0.02 to 0.43) 0.01 (0.00 to 0.04)
All bleeding, on paper only, primary care
Ellis 2005 2 80 9 175 0.18 (0.02 to 0.52) 0.69 (0.63 to 0.74) 0.02 (0.00 to 0.09) 0.05 (0.02 to 0.09)
Mant 1989 5 47 10 75 0.33 (0.12 to 0.62) 0.62 (0.52 to 0.70) 0.10 (0.03 to 0.21) 0.12 (0.06 to 0.21)
Metcalf 1996 2 22 6 69 0.25 (0.03 to 0.65) 0.76 (0.66 to 0.84) 0.08 (0.01 to 0.27) 0.08 (0.03 to 0.17)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
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Table 7 | Diagnostic performance of change of bowel habit and peri-anal symptoms in diagnosis of colorectal cancer
Index test and setting TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
Risk with positive test result
(95% CI)
Risk with negative test result
(95% CI)
Bowel habit
All bleeding, change in bowel habit (CIBH) primary care
Ellis 2005 11 108 0 147 1.00 (0.72 to 1.00) 0.58 (0.51 to 0.64) 0.09 (0.05 to 0.16) 0.00 (0.00 to 0.03)
All bleeding, CIBH too loose/frequent, primary care
Ellis 2005 10 73 1 182 0.91 (0.59 to 1.00) 0.71 (0.65 to 0.77) 0.12 (0.06 to 0.21) 0.01 (0.00 to 0.03)
Fijten 1995 7 71 2 189 0.78 (0.40 to 0.97) 0.73 (0.67 to 0.78) 0.09 (0.04 to 0.18) 0.01 (0.00 to 0.04)
All bleeding, CIBH, primary care
Mant 1989 6 50 10 77 0.38 (0.15 to 0.65) 0.61 (0.52 to 0.69) 0.11 (0.04 to 0.22) 0.12 (0.06 to 0.20)
Metcalf 1996 4 4 35 56 0.10 (0.03 to 0.24) 0.93 (0.84 to 0.98) 0.50 (0.16 to 0.84) 0.39 (0.28 to 0.49)
Norrelund 1996 29 79 21 219 0.58 (0.43 to 0.72) 0.74 (0.68 to 0.78) 0.27 (0.19 to 0.36) 0.09 (0.06 to 0.13)
All bleeding, more frequent or looser stools, primary care
Robertson 2006 13 256 9 310 0.59 (0.36 to 0.79) 0.55 (0.51 to 0.59) 0.05 (0.03 to 0.08) 0.03 (0.01 to 0.05)
Change in bowel habit, secondary care
Bafandeh 2008 1 26 15 438 0.06 (0.00 to 0.30) 0.94 (0.92 to 0.96) 0.04 (0.00 to 0.19) 0.03 (0.02 to 0.05)
Brewster 1994 7 173 14 268 0.33 (0.15 to 0.57) 0.61 (0.56 to 0.65) 0.04 (0.02 to 0.08) 0.05 (0.03 to 0.08)
Farrands 1995 6 52 7 74 0.46 (0.19 to 0.75) 0.59 (0.50 to 0.67) 0.10 (0.04 to 0.21) 0.09 (0.04 to 0.17)
Selvachandran 2002 82 1573 13 600 0.86 (0.78 to 0.93) 0.28 (0.26 to 0.30) 0.05 (0.04 to 0.06) 0.02 (0.01 to 0.04)
Steine 1994 25 799 30 957 0.46 (0.32 to 0.59) 0.55 (0.52 to 0.57) 0.03 (0.02 to 0.04) 0.03 (0.02 to 0.04)
Tan 2002 8 87 50 340 0.14 (0.06 to 0.25) 0.80 (0.76 to 0.83) 0.08 (0.04 to 0.16) 0.13 (0.10 to 0.17)
Tate 1988 9 25 5 91 0.64 (0.35 to 0.87) 0.78 (0.70 to 0.86) 0.27 (0.13 to 0.44) 0.05 (0.02 to 0.12)
Thompson 2007 359 3527 108 4535 0.77 (0.73 to 0.81) 0.56 (0.55 to 0.57) 0.09 (0.08 to 0.10) 0.02 (0.02 to 0.03)
Thompson 2008 599 7439 347 8048 0.63 (0.60 to 0.66) 0.52 (0.51 to 0.53) 0.09 (0.07 to 0.08) 0.04 (0.04 to 0.05)
Zarchy 1991 7 223 16 548 0.30 (0.13 to 0.53) 0.71 (0.68 to 0.74) 0.03 (0.01 to 0.06) 0.03 (0.02 to 0.05)
Change in bowel habit in past 3 months, secondary care
Panzuto 2003 8 49 33 190 0.20 (0.09 to 0.35) 0.80 (0.74 to 0.84) 0.14 (0.06 to 0.26) 0.15 (0.10 to 0.20)
Change in bowel habit as only symptom, secondary care
Thompson 2008 65 1337 881 14 150 0.07 (0.05 to 0.09) 0.91 (0.91 to 0.92) 0.05 (0.04 to 0.06) 0.06 (0.06 to 0.06)
Change in frequency of bowel movements, secondary care
Bjerregaard 2007 77 922 45 1128 0.63 (0.54 to 0.72) 0.55 (0.53 to 0.57) 0.08 (0.06 to 0.10) 0.04 (0.03 to 0.05)
Change in stool consistency, secondary care
Bjerregaard 2007 77 1061 45 989 0.63 (0.54 to 0.72) 0.48 (0.46 to 0.50) 0.07 (0.05 to 0.08) 0.04 (0.03 to 0.06)
All bleeding, diarrhoea, primary care
Metcalf 1996 2 25 6 66 0.25 (0.03 to 0.65) 0.73 (0.62 to 0.81) 0.07 (0.01 to 0.24) 0.08 (0.03 to 0.17)
Diarrhoea, secondary care
Badandeh 2008 1 163 15 301 0.06 (0.00 to 0.30) 0.65 (0.60 to 0.69) 0.01 (0.00 to 0.03) 0.05 (0.03 to 0.08)
Panzuto 2003 10 75 31 164 0.24 (0.12 to 0.40) 0.69 (0.62 to 0.74) 0.12 (0.06 to 0.21) 0.16 (0.11 to 0.22)
Tan 2002 14 89 44 338 0.24 (0.14 to 0.37) 0.79 (0.75 to 0.83) 0.14 (0.08 to 0.22) 0.12 (0.09 to 0.15)
Tate 1988 2 25 12 91 0.14 (0.02 to 0.43) 0.78 (0.70 to 0.86) 0.07 (0.01 to 0.24) 0.12 (0.06 to 0.20)
All constipated, diarrhoea, secondary care
Pepin 2002 2 20 6 535 0.25 (0.03 to 0.65) 0.96 (0.95 to 0.98) 0.09 (0.01 to 0.29) 0.01 (0.00 to 0.02)
All bleeding, constipation , primary care
Metcalf 1996 1 38 7 53 0.13 (0.00 to 0.53) 0.58 (0.47 to 0.69) 0.03 (0.00 to 0.14) 0.12 (0.05 to 0.23)
Constipation, secondary care
Badandeh 2008 2 46 14 418 0.13 (0.02 to 0.38) 0.90 (0.87 to 0.93) 0.04 (0.00 to 0.14) 0.03 (0.02 to 0.05)
Panzuto 2003 21 113 20 126 0.51 (0.35 to 0.67) 0.53 (0.46 to 0.59) 0.16 (0.10 to 0.23) 0.14 (0.09 to 0.20)
Tate 1988 0 16 14 100 0.00 (0.00 to 0.23) 0.86 (0.79 to 0.92) 0.00 (0.00 to 0.21) 0.12 (0.07 to 0.20)
Peri-anal symptoms
All bleeding, peri-anal symptoms, primary care
Ellis 2005 4 199 7 56 0.36 (0.11 to 0.69) 0.22 (0.17 to 0.28) 0.02 (0.01 to 0.05) 0.11 (0.05 to 0.22)
All bleeding, anal (peri-) eczema, primary care
Fijten 1995 3 14 6 246 0.33 (0.08 to 0.70) 0.95 (0.91 to 0.97) 0.18 (0.04 to 0.43) 0.02 (0.01 to 0.05)
All bleeding, anal itch, primary care
Mant 1989 1 35 15 94 0.06 (0.00 to 0.30) 0.73 (0.64 to 0.80) 0.03 (0.03 to 0.15) 0.14 (0.08 to 0.22)
All bleeding, anal protrusion, primary care
Mant 1989 1 29 15 100 0.06 (0.00 to 0.30) 0.78 (0.69 to 0.84) 0.03 (0.00 to 0.17) 0.13 (0.08 to 0.21)
All bleeding, haemorrhoids, primary care
Mant 1989 4 70 12 59 0.25 (0.07 to 0.52) 0.46 (0.37 to 0.55) 0.05 (0.02 to 0.13) 0.17 (0.09 to 0.28)
Peri-anal symptoms, secondary care
Selvachandran 2002 53 1319 42 854 0.56 (0.45 to 0.66) 0.39 (0.37 to 0.41) 0.04 (0.03 to 0.05) 0.05 (0.03 to 0.06)
Thompson 2007 169 4831 298 3231 0.36 (0.32 to 0.41) 0.40 (0.39 to 0.41) 0.03 (0.03 to 0.04) 0.08 (0.08 to 0.09)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
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eight studies confidence intervals for positive and
negative test results did not overlap (table 2, fig 5),
indicating that the risk for colorectal cancer was signif-
icantly higher among those with change in bowel habit
than among thosewithout. 8 29 33 34 44 59 60 71 For diarrhoea
(six studies) sensitivity ranged from 0.06 to 0.25 and
specificity from 0.65 to 0.79,27 45 55 70 71 with the excep-
tion of the study of Pepin et al, 46 with a specificity of
0.96 (table 7). That study, however, used constipation
as inclusion criterion. For constipation (four
studies) 27 45 70 71 sensitivity ranged from 0.00 to 0.51
and specificity from 0.53 to 0.90.
For peri-anal symptoms (five studies) the diagnostic
performancedependedon thedefinitionused (table 7).
When anal itch or anal protrusion was studied,40 sensi-
tivity was significantly lower (0.06) than when a more
general definition such as peri-anal symptoms was
used (0.36 to 0.56). 8 33 59 Patients with peri-anal symp-
toms might have a lower risk of colorectal cancer than
patients without such symptoms, although the oppo-
site might be true for the presence of peri-anal
eczema.34
Of the remaining symptoms (table 8) the presence of
“mucusmixedwith blood”might be informative as the
risk of colorectal cancer was 14% for those reporting
this symptom comparedwith 3% for thosewithout, but
only one study investigated it. 8
Diagnostic performance of symptom combinations
Five primary care,33 34 44 49 63 three primary-secondary
interface,28 65 68 and four secondary care
studies8 28 41 59 60 65 68 presented diagnostic data on a
whole range of symptom combinations, including
two classification systems that were originally devel-
oped to differentiate organic from non-organic disease
Table 8 | Diagnostic performance of various gastrointestinal symptoms (other than those detailed in tables 3-7) in diagnosis of colorectal cancer
Index test and setting TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Urgency, secondary care
Selvachandran 2002 38 530 57 1643 0.40 (0.30 to 0.51) 0.76 (0.74 to 0.77) 0.07 (0.05 to 0.09) 0.03 (0.03 to 0.04)
Abdominal distension, secondary care
Steine 1994 36 1352 19 434 0.66 (0.51 to 0.78) 0.24 (0.22 to 0.26) 0.03 (0.02 to 0.04) 0.04 (0.03 to 0.07)
Bloating, secondary care
Panzuto 2003 22 147 19 92 0.54 (0.37 to 0.69) 0.39 (0.32 to 0.45) 0.13 (0.08 to 0.19) 0.17 (0.11 to 0.25)
All bleeding, incomplete evacuation, primary care
Mant 1989 5 37 11 92 0.31 (0.11 to 0.59) 0.71 (0.63 to 0.79) 0.12 (0.04 to 0.26) 0.11 (0.06 to 0.18)
Incomplete evacuation, secondary care
Selvachandran 2002 47 827 48 1346 0.50 (0.39 to 0.60) 0.62 (0.60 to 0.64) 0.05 (0.04 to 0.07) 0.03 (0.03 to 0.05)
Bjerregaard 2007 66 968 56 1082 0.54 (0.45 to 0.63) 0.53 (0.51 to 0.55) 0.06 (0.05 to 0.08) 0.05 (0.04 to 0.06)
All bleeding, associated slime, primary care
Metcalf 1996 3 25 5 66 0.38 (0.09 to 0.76) 0.73 (0.62 to 0.81) 0.11 (0.02 to 0.28) 0.07 (0.02 to 0.16)
Mucus, secondary care
Bjerregaard 2007 40 555 82 1495 0.33 (0.25 to 0.42) 0.73 (0.71 to 0.75) 0.07 (0.05 to 0.09) 0.05 (0.04 to 0.06)
Mucus alone, secondary care
Selvachandran 2002 16 416 79 1757 0.17 (0.10 to 0.26) 0.81 (0.79 to 0.83) 0.04 (0.02 to 0.06) 0.04 (0.03 to 0.05)
Mucus mixed with blood, secondary care
Selvachandran 2002 38 238 57 1935 0.40 (0.30 to 0.51) 0.89 (0.88 to 0.90) 0.14 (0.10 to 0.18) 0.03 (0.02 to 0.04)
All bleeding, painful defecation, primary care
Mant 1989 2 28 14 101 0.13 (0.02 to 0.38) 0.78 (0.70 to 0.85) 0.07 (0.01 to 0.22) 0.12 (0.07 to 0.20)
Painful defecation, secondary care
Selvachandran 2002 11 441 84 1732 0.12 (0.06 to 0.20) 0.80 (0.78 to 0.81) 0.02 (0.01 to 0.04) 0.05 (0.04 to 0.06)
All bleeding, pain at night, primary care
Fijten 1995 0 50 9 210 0.00 (0.00 to 0.34) 0.81 (0.75 to 0.85) 0.00 (0.00 to 0.07) 0.04 (0.02 to 0.08)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
Bafandeh 2008
Bjerregaard 2007
Brewster 1994
Farrands 1995
Panzuto 2003
Selvachandran 2002
Steine 1994
Tan 2002
Tate 1988
Thompson 2007
Thompson 2008
Zarchy 1991
Pepin 2002
Pooled estimate
0 0.1 0.2 0.40.3
Positive predictive value (PPV)
0 0.1 0.2 0.40.3
1–negative predictive value (1–NPV)
Fig 3 | Risk of colorectal cancer in patients with rectal bleeding (positive predictive value)
versus risk in those without rectal bleeding (1−negative predictive value); all studies
conducted in secondary care
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Table 9 | Diagnostic performance of symptom combinations and referral guidelines in diagnosis of colorectal cancer
Index test and setting TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Symptom combinations
All bleeding, CIBH, abdominal pain, primary care
Ellis 2005 6 61 5 194 0.55 (0.23 to 0.83) 0.76 (0.70 to 0.81) 0.09 (0.03 to 0.19) 0.03 (0.01 to 0.06)
All bleeding, prediction model including age, CIBH, blood mixed with or on stool, primary care
Fijten 1995 9 26 0 234 1.00 (0.66 to 1.00) 0.90 (0.86 to 0.93) 0.26 (0.13 to 0.43) 0.00 (0.00 to 0.03)
All bleeding, CIBH, age >69, primary care
Norrelund 1996 19 27 31 271 0.38 (0.25 to 0.53) 0.91 (0.87 to 0.94) 0.41 (0.27 to 0.57) 0.10 (0.07 to 0.14)
All bleeding, dark and mixed with stool, primary care
Robertson 2006 9 79 13 503 0.41 (0.21 to 0.64) 0.86 (0.83 to 0.89) 0.10 (0.05 to 0.19) 0.03 (0.01 to 0.04)
Bleeding, CIBH*
Chohan 2005 29 123 35 275 0.45 (0.33 to 0.58) 0.69 (0.64 to 0.74) 0.19 (0.13 to 0.26) 0.11 (0.08 to 0.15)
Bleeding, CIBH, >6 weeks to looser/more frequent*
Flashman 2004, GP findings 28 174 37 456 0.43 (0.31 to 0.56) 0.72 (0.69 to 0.76) 0.14 (0.09 to 0.19) 0.08 (0.05 to 0.10)
Flashman2004, clinic findings 26 144 39 486 0.40 (0.28 to 0.53) 0.77 (0.74 to 0.80) 0.15 (0.10 to 0.22) 0.07 (0.05 to 0.10)
Bleeding, CIBH >6 weeks, age >45*
Barwick 2004 3 45 11 85 0.21 (0.05 to 0.51) 0.65 (0.57 to 0.74) 0.06 (0.01 to 0.17) 0.12 (0.06 to 0.20)
Bleeding, no peri-anal symptoms, age >60*
Flashman 2004-GP findings 17 143 48 487 0.26 (0.16 to 0.39) 0.96 (0.92 to 0.99) 0.13 (0.08 to 0.18) 0.09 (0.07 to 0.12)
Flashman 2004-clinic findings 4 27 61 603 0.06 (0.02 to 0.15) 0.96 (0.94 to 0.97) 0.13 (0.04 to 0.30) 0.09 (0.07 to 0.12)
Bleeding, no peri-anal symptoms, age >55*
Chohan 2005 37 164 27 234 0.58 (0.45 to 0.70) 0.59 (0.54 to 0.64) 0.18 (0.13 to 0.25) 0.10 (0.07 to 0.15)
Bleeding, no peri-anal symptoms, age >65*
Barwick 2004 3 25 11 105 0.21 (0.05 to 0.51) 0.81 (0.73 to 0.87) 0.11 (0.02 to 0.28) 0.10 (0.05 to 0.16)
CIBH >6 weeks to looser/more frequent*
Chohan 2005 27 171 37 227 0.42 (0.30 to 0.55) 0.57 (0.52 to 0.62) 0.14 (0.09 to 0.19) 0.14 (0.10 to 0.19)
CIBH >6 weeks to looser/more frequent, age >45*
Barwick 2004 5 65 9 65 0.36 (0.13 to 0.65) 0.50 (0.41 to 0.59) 0.07 (0.02 to 0.16) 0.12 (0.06 to 0.22)
CIBH >6 weeks, no bleeding, age >60*
Flashman 2004 - GP findings 17 261 48 369 0.26 (0.16 to 0.39) 0.59 (0.55 to 0.62) 0.06 (0.04 to 0.10) 0.12 (0.09 to 0.15)
Flashman2004-clinic findings 11 161 54 469 0.17 (0.09 to 0.28) 0.74 (0.71 to 0.78) 0.06 (0.03 to 0.11) 0.10 (0.08 to 0.13)
All bleeding, at least 1 of: dark red, large volume, mixed with stool, streaked on stool, family history, personal history , CIBH, mucus, anaemia, or FOBT, secondary care
Marderstein 2008 19 503 7 696 0.73 (0.88 to 0.52) 0.58 (0.61 to 0.55) 0.04 (0.02 to 0.06) 0.01 (0.00 to 0.02)
Bleeding, CIBH, secondary care
Thompson 2007 249 1802 218 6260 0.53 (0.49 to 0.58) 0.78 (0.77 to 0.79) 0.12 (0.11 to 0.14) 0.03 (0.03 to 0.04)
Thompson 2008 466 4096 480 11391 0.49 (0.46 to 0.53) 0.74 (0.73 to 0.74) 0.10 (0.09 to 0.11) 0.04 (0.04 to 0.04)
Bleeding, CIBH, peri-anal symptoms, secondary care
Thompson 2007 101 1200 366 6862 0.22 (0.18 to 0.26) 0.85 (0.84 to 0.86) 0.08 (0.06 to 0.09) 0.05 (0.05 to 0.06)
Bleeding, CIBH, no peri-anal symptoms, secondary care
Thompson 2007 148 602 319 7460 0.32 (0.28 to 0.36) 0.93 (0.92 to 0.93) 0.20 (0.17 to 0.23) 0.04 (0.04 to 0.05)
Bleeding, CIBH, abdominal pain, secondary care
Thompson 2007 101 1068 366 6994 0.22 (0.18 to 0.26) 0.87 (0.86 to 0.88) 0.09 (0.07 to 0.10) 0.05 (0.05 to 0.06)
Bleeding, CIBH, abdominal pain, secondary care
Thompson 2008 181 2696 765 12791 0.19 (0.17 to 0.22) 0.83 (0.82 to 0.83) 0.06 (0.05 to 0.07) 0.06 (0.05 to 0.06)
Bleeding, CIBH, no abdominal pain, secondary care
Thompson 2007 148 734 319 7328 0.32 (0.28 to 0.36) 0.91 (0.90 to 0.92) 0.17 (0.14 to 0.19) 0.04 (0.04 to 0.05)
Bleeding, no CIBH, secondary care
Thompson 2007 84 3277 383 4785 0.18 (0.15 to 0.22) 0.59 (0.58 to 0.60) 0.03 (0.02 to 0.03) 0.07 (0.07 to 0.08)
Bleeding, no CIBH, peri-anal symptoms, secondary care
Thompson 2007 37 2515 430 5547 0.08 (0.06 to 0.11) 0.69 (0.68 to 0.70) 0.01 (0.01 to 0.02) 0.07 (0.07 to 0.08)
Bleeding, no CIBH, no peri-anal symptoms, secondary care
Thompson 2007 47 762 420 7300 0.10 (0.08 to 0.13) 0.91 (0.90 to 0.91) 0.06 (0.04 to 0.08) 0.05 (0.05 to 0.06)
Bleeding, abdominal pain, secondary care
Thompson 2008 227 4140 719 11347 0.24 (0.21 to 0.27) 0.73 (0.73 to 0.74) 0.05 (0.05 to 0.06) 0.06 (0.06 to 0.06)
Bleeding, peri-anal symptoms, secondary care
Thompson 2007 138 3715 329 4347 0.30 (0.25 to 0.34) 0.54 (0.53 to 0.55) 0.04 (0.03 to 0.04) 0.07 (0.06 to 0.08)
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(Bellentani and Kruis criteria63), a self developed pre-
diction rule by Fijten et al,34 and an experience based
scoring method to predict colorectal cancer (Selva
score8) (table 9). The three primary-secondary inter-
face studies presented diagnostic data on individual
referral criteria of the two week referral guideline.
Sensitivity ranged from 0.03 for a combination of
abdominal pain without rectal bleeding or change in
bowel habit,59 to a sensitivity of 1.00 for a prediction
rule including age, change in bowel habit, and blood
mixed with or on stool.34 Specificity ranged from 0.50
for a combination of change in bowel habit and age
≥4528 to a specificity of 0.96 for a combination of rectal
bleeding, (absence of) peri-anal symptoms, and age
≥60.68 A prediction rule showed favourable results for
both sensitivity (1.00) and specificity (0.90).34
Thompson et al found that the risk of colorectal can-
cer increased from 6% to 12% when rectal bleeding is
accompaniedby a change in bowel habit.59When addi-
tional information was gathered on peri-anal symp-
toms and they are absent, the risk increased further to
20%. When rectal bleeding was accompanied by peri-
anal symptoms but not by a change in bowel habit, the
risk of colorectal cancer decreased from 6% to 1%.59
Four studies evaluated the two week referral guide-
line in a two week referral clinic and two studies in
secondary care (see appendix A for a description of
the guideline). The formulation of the two week refer-
ral criteria differed (slightly) across studies. Selvachan-
dran et al included only three of the six criteria.8
Sensitivity ranged from 0.80 for the abridged version8
to 0.9469; specificity ranged from 0.3065 to 0.56.69 For
thosemeeting the guideline (that is, positive score on at
0 0.1 0.2 0.40.3
Positive predictive value (PPV)
0 0.1 0.2 0.40.3
1–negative predictive value (1–NPV)
Primary care
Ellis 2005
Mant 1989
Metcalf 1996
Robertson 2006
Secondary care
Bjerregaard 2007
Pooled estimate
Fig 4 | Risk of colorectal cancer in patients with rectal bleeding/dark blood (positive predictive
value) versus risk in those without rectal bleeding/dark blood (1−negative predictive value)
Index test and setting TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Bleeding, no peri-anal symptoms, secondary care
Thompson 2007 195 1364 272 6698 0.42 (0.37 to 0.46) 0.83 (0.82 to 0.84) 0.13 (0.11 to 0.14) 0.04 (0.04 to 0.04)
CIBH, no bleeding, secondary care
Thompson 2007 110 1725 357 6337 0.24 (0.20 to 0.28) 0.79 (0.78 to 0.80) 0.06 (0.05 to 0.07) 0.05 (0.05 to 0.06)
CIBH, no bleeding, abdominal pain, secondary care
Thompson 2007 40 726 427 7336 0.09 (0.06 to 0.12) 0.91 (0.90 to 0.92) 0.05 (0.04 to 0.07) 0.06 (0.05 to 0.06)
Abdominal pain, CIBH, secondary care
Thompson 2008 246 4525 700 10962 0.26 (0.23 to 0.29) 0.71 (0.70 to 0.72) 0.05 (0.05 to 0.06) 0.06 (0.06 to 0.06)
Abdominal pain, no CIBH, no bleeding, secondary care
Thompson 2007 16 634 451 7428 0.03 (0.02 to 0.06) 0.92 (0.92 to 0.93) 0.03 (0.01 to 0.04) 0.06 (0.05 to 0.06)
Selva score, secondary care, Selvachandran 2002†
≥40 v <40 151 1733 5 1413 0.97 (0.93 to 0.99) 0.45 (0.43 to 0.47) 0.08 (0.07 to 0.09) 0.00 (0.00 to 0.01)
≥50 v <50 134 1167 22 1979 0.86 (0.79 to 0.91) 0.63 (0.61 to 0.65) 0.10 (0.09 to 0.12) 0.01 (0.01 to 0.02)
≥60 v <60 72 495 23 1678 0.76 (0.66 to 0.84) 0.77 (0.75 to 0.79) 0.13 (0.10 to 0.16) 0.01 (0.01 to 0.02)
≥70 v <70 66 266 29 1907 0.70 (0.59 to 0.79) 0.88 (0.86 to 0.89) 0.20 (0.16 to 0.25) 0.02 (0.01 to 0.02)
Bellentani >0, primary care
Bellentani 1990 10 111 0 133 1.00 (0.69 to 1.00) 0.55 (0.48 to 0.61) 0.08 (0.04 to 0.15) 0.00 (0.00 to 0.03)
Kruis <44, primary care
Bellentani 1990 9 84 1 160 0.90 (0.56 to 1.00) 0.66 (0.59 to 0.72) 0.10 (0.05 to 0.18) 0.01 (0.00 to 0.03)
Guidelines fulfilled
Two week referral guideline, two week referral clinic
Chohan 2005 59 278 5 120 0.92 (0.83 to 0.97) 0.30 (0.26 to 0.35) 0.18 (0.14 to 0.22) 0.04 (0.01 to 0.09)
Debnath 2002 18 129 3 87 0.86 (0.64 to 0.97) 0.40 (0.34 to 0.47) 0.12 (0.07 to 0.19) 0.03 (0.01 to 0.09)
Eccersley 2003 24 71 2 83 0.92 (0.75 to 0.99) 0.54 (0.46 to 0.62) 0.25 (0.17 to 0.35) 0.02 (0.00 to 0.08)
Flashman 2004 58 363 7 267 0.89 (0.79 to 0.96) 0.42 (0.39 to 0.46) 0.14 (0.11 to 0.17) 0.03 (0.01 to 0.05)
Two week referral guideline, secondary care
Mahon 2002 17 102 1 127 0.94 (0.73 to 1.00) 0.56 (0.49 to 0.62) 0.14 (0.09 to 0.22) 0.01 (0.00 to 0.04)
Adjusted two week referral guideline (only 3 criteria) secondary care
Selvachandran 2002† 125 1444 31 1702 0.80 (0.73 to 0.86) 0.54 (0.52 to 0.56) 0.08 (0.07 to 0.09) 0.02 (0.01 to 0.03)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives; CIBH=change in bowel habit; FOBT=faecal occult blood test.
*Two week referral criterion.
†For this study we extracted data for some index tests from a more recent paper of Hodder et al.72
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least one of the six criteria) the risk varied from 8%8 to
25%67 with amedian of 14%,while for patients who did
notmeet the guideline the risk varied from1%69 to 4%65
with a median of 3% (table 2, fig 6).
Diagnostic performance of blood tests
Eight studies reported on the diagnostic value of iron
deficiency anaemia,27 2945 46 55 65 68 71 and one primary
care study34 on the diagnostic value of haemoglobin,
erythrocyte sedimentation rate, and white cell count
(table 10). For (iron deficiency) anaemia sensitivity
varieswidely from0.07 to 0.68,while specificity ranges
from 0.83 to 0.95. In three of the eight studies the risk
for colorectal cancer was significantly higher among
those with a positive test result than among those with
a negative test result (table 2, fig 7). 27 45 65
Diagnostic performance of faecal occult blood test
Table 11 gives details of the 15 studies that reported on
the diagnostic performance of guaiac based faecal
occult blood tests, 11 12 31 34-38 43 47 48 53 56-58 three studies
on do-it-yourself tests, 48 56 57 eight studies on immuno-
chemical based faecal occult blood tests, 36 39 42 47 50-53 58
and one study on a combination of the occult blood
tests. 47 Few studies reported detailed information on
diet restrictions before the test.
For guaiac based tests sensitivity ranged from 0.33
for the Coloscreen self test48 to 1.00 for a Haemoccult
test,12 while specificity ranged from 0.72 for a Fecatwin
test57 to 0.94 for theColoscreen self test.48 Sensitivity of
the self tests was low (range 0.33-0.57). For immuno-
chemical based faecal occult blood tests sensitivity ran-
ged from 0.70 for an iFOBT strip device50 to 1.00 for
HemeSelect, Hemoblot, Insure, and faecal
haemoglobin.36 39 53 Specificity ranged from 0.71 for a
haemoglobin-albumin complex51 to 0.93 for an iFOBT
strip device.50
The risk for colorectal cancer was significantly
higher among patients with a positive test result than
among those with a negative test result, with the excep-
tion of the study of Fijten et al34 (table 11) that included
solely patients with rectal bleeding. For guaiac based
tests themedian risk was 0.28 among those with a posi-
tive test result and 0.01 for those with a negative test
result, while these numberswere 0.21 and 0.00, respec-
tively for immunochemical based tests (table 2, figs 8
and 9).
Preplanned subgroup analyses
Because of lack of data in one or both subgroups sev-
eral preplanned subgroup analyses could not be car-
ried out. Table 12 presents the results of the
subgroup analyses between studies for which sufficient
data were available. Comparing the subgroups’
(ranges of) values of sensitivity and specificity shows
that none of the factors was clearly able to explain the
tests’ heterogeneous results.
We looked at several subgroup analyses within stu-
dies. Sensitivity of the immunochemical based faecal
occult blood tests was better than that of the guaiac
based tests,36 53 58 and better for the regular guaiac
based tests than the self tests (table 13). 48 56 57 These
findings are confirmed by the between study findings
(table 2). Subgroup analyses within studies onDukes’s
types stages showed that immunochemical based tests
were better than guaiac based tests in detecting
Dukes’s A and B,53 58 and sensitivity seemed to be
higher at all locations. 58 This, however, was based on
one or two studies with a small number of cases
(table 14).
DISCUSSION
The performance of tests in diagnosing colorectal can-
cer in adult patientswith symptomsvariedwidely. Sen-
sitivity was consistently high for age ≥50 (range 0.81-
0.96, median 0.91) and for the twoweek referral guide-
line (range 0.80-0.94, median 0.92), but these lacked
specificity (medians 0.36 and 0.42, respectively).
These tests are suitable to rule out colorectal cancer at
the cost of a high number of patients needing further
diagnostic testing. Specificity was consistently high for
family history (range 0.75-0.98, median 0.91), weight
loss (range 0.72-0.96, median 0.89), and iron defi-
ciency anaemia (0.83-0.95, median 0.92), but all tests
lacked sensitivity (medians 0.16, 0.20 and 0.13, respec-
tively). These tests are suitable to rule in colorectal can-
cer but at the cost of missing a considerable proportion
of cases.Only the immunochemical based faecal occult
blood tests had both a reasonable sensitivity (range
0.70-1.00, median 0.95) and specificity (range 0.71-
0.93, median 0.84).
Diagnostic tests for colorectal cancer in primary care
This review focuses on the diagnostic performance of
tests for patients who present with non-acute lower
abdominal symptoms in primary care. We found that
0 0.2 0.4 0.8 1.00.6 0 0.2 0.4 0.8 1.00.6
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Fig 5 | Risk of colorectal cancer in patients reporting change in bowel habit (positive predictive
value) versus risk in patients not reporting this symptom (1−negative predictive value)
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only a few studies were clearly carried out in primary
care populations. We excluded screening studies,
which would also include a large proportion of people
without symptoms. Screening is useful if early stages of
colorectal cancer can be detected,which have a favour-
able prognosis. In primary care, all colorectal cancer
should be diagnosed, and preferably at an early stage.
Therefore, it is useful to make a distinction between
early stages (Dukes’s A/B)—that is, resectable colorec-
tal cancer—and later stages (Dukes’s C/D). Some of
the tests reflect symptomsof later stages, such asweight
loss and irondeficiency anaemia, andwill thereforenot
help to identify early stages of colorectal cancer.
When a patient presents to primary care with
abdominal symptoms several differential diagnoses
can be considered (such as colorectal cancer, irritable
bowel syndrome, coeliac disease) and general practi-
tioners should identify patients who should be referred
for further diagnosis.Our review focused on colorectal
cancer, yet to the clinician a positive test result (such as
diarrhoea) leading to a diagnosis of inflammatory dis-
ease might be considered a true positive result.
Primary care settings differ between countries, and
in only a few countries do general practitioners act as a
gatekeeper to specialist clinical care. In other countries
specialist caremaybe directly accessible. Thereforewe
also included two week referral clinics and secondary
care populations with a low prevalence of colorectal
cancer, which might reflect populations with a similar
spectrum of disease as in primary care and a limited
risk of investigation bias. Many studies, both in pri-
mary and secondary care settings, however, enrolled
a selective population of patients by using the presence
of a specific complaint as an inclusion criterion. For
example, seven primary care studies investigating the
diagnostic performance of signs and symptoms used
rectal bleeding as an inclusion criterion.We presented
the findings in such a way that differences between set-
tings and populations can be easily identified.
Diagnostic performance
Symptoms and signs
Of the typical symptoms of colorectal cancer, only
weight loss had some diagnostic value with a fairly
high specificity. This seemed to be translated in clear
differences between the probability of colorectal can-
cer among patients with or without apparent weight
loss (positive predictive value v 1−negative predictive
Table 10 | Diagnostic performance of blood tests in diagnosis of colorectal cancer
Index test and setting TP FP FN TN
Sensitivity
(95% CI)
Specificity
(95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Iron deficiency anaemia (haemoglobin <6.2 mmol/l in men and postmenopausal women), two week referral clinic
Chohan 2005 13 25 51 373 0.20 (0.11 to 0.32) 0.94 (0.91 to 0.96) 0.34 (0.20 to 0.51) 0.12 (0.09 to 0.16)
Iron deficiency anaemia (haemoglobin ≤6.2 mmol/l in women aged >50, ≤6.8 mmol/l in men), two week referral clinic
Flashman 2004, GP findings 6 49 59 581 0.09 (0.04 to 0.19) 0.92 (0.90 to 0.94) 0.11 (0.04 to 0.22) 0.09 (0.07 to 0.12)
Flashman 2004, clinic findings 6 47 59 583 0.09 (0.04 to 0.19) 0.93 (0.90 to 0.95) 0.11 (0.04 to 0.23) 0.09 (0.07 to 0.12)
Unexplained anaemia, present v absent, secondary care
Badandeh 2008 5 30 11 434 0.31 (0.11 to 0.59) 0.94 (0.91 to 0.96) 0.14 (0.05 to 0.30) 0.03 (0.01 to 0.04)
Anaemia, secondary care
Bjerregaard 2007 14 197 108 1853 0.12 (0.06 to 0.19) 0.90 (0.89 to 0.92) 0.07 (0.04 to 0.11) 0.06 (0.05 to 0.07)
Iron deficiency anaemia (haemoglobin <8.7 mmol/l in men, <7.5 mmol/l in women; ferritin <6.7 pmol/l), secondary care
Panzuto 2003 28 41 13 198 0.68 (0.52 to 0.82) 0.83 (0.78 to 0.87) 0.41 (0.29 to 0.53) 0.06 (0.03 to 0.10)
Iron deficiency anaemia present v absent, secondary care
Tan 2002 8 35 50 392 0.14 (0.06 to 0.25) 0.92 (0.89 to 0.94) 0.19 (0.08 to 0.33) 0.11 (0.09 to 0.15)
(Iron deficiency) anaemia, secondary care
Tate 1988 1 10 13 106 0.07 (0.00 to 0.34) 0.91 (0.85 to 0.96) 0.09 (0.00 to 0.41) 0.11 (0.06 to 0.18)
All constipated, anaemia, secondary care
Pepin 2002 1 27 7 528 0.13 (0.00 to 0.53) 0.95 (0.93 to 0.97) 0.04 (0.00 to 0.18) 0.01 (0.01 to 0.03)
All bleeding, haemoglobin <8.5 mmol/l in men, <7.5 mmol/l in women, primary care
Fijten 1995 2 12 3 208 0.40 (0.05 to 0.85) 0.95 (0.91 to 0.97) 0.14 (0.02 to 0.43) 0.01 (0.00 to 0.04)
All bleeding, erythrocyte sedimentation rate >30 mm in first hour, primary care
Fijten 1995 2 10 3 210 0.40 (0.05 to 0.85) 0.96 (0.92 to 0.98) 0.17 (0.02 to 0.48) 0.01 (0.00 to 0.04)
All bleeding, white cell count >109/l, primary care
Fijten 1995 3 22 2 192 0.60 (0.15 to 0.95) 0.90 (0.85 to 0.93) 0.12 (0.03 to 0.31) 0.01 (0.00 to 0.04)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
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Fig 6 | Risk of colorectal cancer in patients meeting two week referral rule (positive predictive
value) versus risk in those not meeting two week referral (1−negative predictive value)
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Table 11 | Diagnostic performance of faecal occult blood tests in diagnosis of colorectal cancer
Index test and setting TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
Risk with positive test
result (95% CI)
Risk with negative test
result (95% CI)
Positive v negative result on guaiac based faecal occult blood test
Haemoccult II, diet, primary care
Castiglione 1987 17 79 13 746 0.57 (0.37 to 0.75) 0.90 (0.88 to 0.92) 0.18 (0.11 to 0.27) 0.02 (0.01 to 0.03)
All bleeding, Haemoccult, diet, primary care
Fijten 1995 2 39 3 181 0.40 (0.05 to 0.85) 0.82 (0.77 to 0.87) 0.05 (0.01 to 0.17) 0.02 (0.00 to 0.05)
Fecatwin/Feca, no info on diet, secondary care
Pye 1989 18 109 6 402 0.75 (0.53 to 0.90) 0.79 (0.75 to 0.82) 0.14 (0.09 to 0.22) 0.02 (0.01 to 0.03)
Fecatwin, no info on diet secondary care
Tate 1990 14 91 1 229 0.93 (0.68 to 1.00) 0.72 (0.66 to 0.76) 0.13 (0.08 to 0.21) 0.00 (0.00 to 0.02)
Haemoccult, diet, secondary care
Goulston 1980 8 16 2 72 0.80 (0.44 to 0.98) 0.82 (0.72 to 0.89) 0.33 (0.16 to 0.55) 0.03 (0.00 to 0.09)
Thomas 1992 29 20 21 262 0.58 (0.43 to 0.72) 0.93 (0.89 to 0.96) 0.59 (0.44 to 0.73) 0.07 (0.05 to 0.11)
Haemoccult, no diet, secondary care
Falkson 1993 19 32 4 403 0.83 (0.61 to 0.95) 0.93 (0.90 to 0.95) 0.37 (0.24 to 0.52) 0.01 (0.00 to 0.03)
Jeanson 1994 8 22 3 102 0.73 (0.39 to 0.94) 0.82 (0.74 to 0.89) 0.27 (0.12 to 0.46) 0.03 (0.01 to 0.08)
Kimmig 1989 22 139 2 371 0.92 (0.73 to 0.99) 0.73 (0.69 to 0.77) 0.14 (0.09 to 0.20) 0.01 (0.00 to 0.02)
Leicester 1983 28 108 9 597 0.76 (0.59 to 0.88) 0.85 (0.82 to 0.87) 0.21 (0.14 to 0.28) 0.02 (0.01 to 0.03)
Haemoccult, no info on diet, secondary care
Farrands 1985 13 21 0 105 1.00 (0.75 to 1.00) 0.83 (0.76 to 0.89) 0.38 (0.22 to 0.56) 0.00 (0.00 to 0.04)
Pye 1990 13 31 11 328 0.54 (0.33 to 0.74) 0.91 (0.88 to 0.94) 0.30 (0.17 to 0.45) 0.03 (0.02 to 0.06)
Tate 1989 12 30 3 230 0.80 (0.52 to 0.96) 0.89 (0.84 to 0.92) 0.29 (0.16 to 0.45) 0.01 (0.00 to 0.04)
Tate 1990 16 33 4 262 0.80 (0.56 to 0.94) 0.89 (0.85 to 0.92) 0.33 (0.20 to 0.48) 0.02 (0.00 to 0.04)
Haemoccult II, diet, secondary care
Niv 1995 9 114 4 312 0.69 (0.39 to 0.91) 0.73 (0.69 to 0.77) 0.07 (0.03 to 0.13) 0.01 (0.00 to 0.03)
Haemoccult II Sensa, diet, secondary care
Smith 2006 5 19 2 135 0.71 (0.29 to 0.96) 0.88 (0.81 to 0.92) 0.21 (0.07 to 0.42) 0.02 (0.00 to 0.05)
Self-Test Coloscreen, no info on diet, secondary care
Pye 1990 8 22 16 331 0.33 (0.16 to 0.55) 0.94 (0.91 to 0.96) 0.27 (0.12 to 0.46) 0.05 (0.03 to 0.07)
Self-Test E-Z Detect, no info on diet, secondary care
Tate 1989 8 41 14 341 0.36 (0.17 to 0.59) 0.89 (0.86 to 0.92) 0.16 (0.07 to 0.30) 0.04 (0.02 to 0.07)
Tate 1990 8 34 6 271 0.57 (0.29 to 0.82) 0.89 (0.85 to 0.92) 0.19 (0.09 to 0.34) 0.02 (0.01 to 0.05)
Positive v negative result on immunochemical based faecal occult blood test
HemeSelect, secondary care
Jeanson 1994 11 24 0 100 1.00 (0.72 to 1.00) 0.81 (0.73 to 0.87) 0.31 (0.17 to 0.49) 0.00 (0.00 to 0.04)
Thomas 1992 47 62 3 220 0.94 (0.84 to 0.99) 0.78 (0.73 to 0.83) 0.43 (0.34 to 0.53) 0.01 (0.00 to 0.04)
Hemoblot, secondary care
Jeanson 1994 11 29 0 95 1.00 (0.72 to 1.00) 0.77 (0.68 to 0.84) 0.28 (0.15 to 0.44) 0.00 (0.00 to 0.04)
iFOBT strip device, secondary care
Shastri 2008 37 26 16 334 0.70 (0.56 to 0.82) 0.93 (0.90 to 0.95) 0.59 (0.46 to 0.71) 0.05 (0.03 to 0.07)
Immunohemostick, secondary care
Miyoshi 2000 11 140 3 1144 0.79 (0.49 to 0.95) 0.89 (0.87 to 0.91) 0.07 (0.04 to 0.13) 0.00 (0.00 to 0.01)
InSure, secondary care
Smith 2006 7 30 0 124 1.00 (0.59 to 1.00) 0.81 (0.73 to 0.87) 0.19 (0.08 to 0.35) 0.00 (0.00 to 0.03)
Faecal haemoglobin albumin >2 μg/g faeces, secondary care
Sieg 1998 41 204 2 492 0.95 (0.84 to 0.99) 0.71 (0.67 to 0.74) 0.17 (0.12 to 0.22) 0.00 (0.00 to 0.02)
Sieg 1999 19 115 4 483 0.83 (0.61 to 0.95) 0.81 (0.77 to 0.84) 0.14 (0.09 to 0.21) 0.01 (0.00 to 0.02)
Faecal haemoglobin >75 ng/ml, secondary care
Levi 2007 6 61 0 404 1.00 (0.54 to 1.00) 0.87 (0.84 to 0.90) 0.09 (0.03 to 0.19) 0.00 (0.00 to 0.01)
Faecal haemoglobin >10 μg/g faeces, secondary care
Sieg 1998 41 167 2 529 0.95 (0.84 to 0.99) 0.76 (0.73 to 0.79) 0.20 (0.15 to 0.26) 0.00 (0.00 to 0.01)
Sieg 1999 20 71 3 527 0.87 (0.66 to 0.97) 0.88 (0.85 to 0.91) 0.22 (0.14 to 0.32) 0.01 (0.00 to 0.02)
Combination tests, positive v negative result
Fecatwin/Feca EIA, no info on diet (combined guaiac and immunochemical), secondary care
Pye 1989 16 52 8 459 0.67 (0.45 to 0.84) 0.90 (0.87 to 0.92) 0.24 (0.14 to 0.35) 0.02 (0.01 to 0.03)
TP=true positives; FP=false positives; FN=false negatives; TN=true negatives.
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value). Other symptoms, including presence of diar-
rhoea, constipation, change in bowel habit, or abdom-
inal pain, showed poor diagnostic performance.
Studies showed a high degree of heterogeneity. This
might be because studies used different definitions to
classify self reported symptoms such as change in
bowel habit. Furthermore, studies used different inclu-
sion criteria, leading to an increased risk of selection
bias in several studies. For example, in seven out of
10 primary care studies that reported on the diagnostic
performance of signs and symptoms in symptomatic
patients, rectal bleeding was used as inclusion
criterion, thereby selecting a higher risk group. It is
unlikely that the results of these studies are directly
applicable to all primary care patients consulting
their general practitioner with lower abdominal signs
and symptoms.
Family history
Family history showed a high specificity combined
with a low sensitivity. Its diagnostic value in primary
care is limited, however, because only a small percen-
tage of all cases have a family history. In the UK and
other countries patients with a familial link are often
referred for genetic assessment instead of immediate
investigation with colonoscopy, which often results in
a screening advice. TheNICE guidelines for colorectal
cancer state that there is insufficient evidence for the
value of family history in symptomatic patients.73 The
few studies in our review that presented information on
family history showed heterogeneous results for diag-
nostic performance. To firmly establish the diagnostic
performance of family history in symptomatic patients
we need a clear definition for a “positive family his-
tory,” which describes the number, age, and degree
of affected family members.
Combinations of symptoms and two week referral
guidelines
Our results indicate that while the diagnostic perfor-
mance of individual signs and symptoms is limited,
Table 12 | Results of preplanned subgroup analyses between studies
Analyses (No of studies)
Sensitivity (range or pooled
estimate (95% CI)*)
Specificity (range or pooled estimate
(95% CI)*)
1st subgroup 2nd subgroup 1st subgroup 2nd subgroup
Weight loss
Primary (6) v secondary care (6) 0.13-0.44 0.23 (0.17-0.30) 0.85-0.94 0.90 (0.84 to 0.93)
Prevalence <5% (6) v ≥5% (7) 0.21 (0.15 to 0.29) 0.13-0.37 0.91 (0.86 to 0.94) 0.72-0.94
QUADAS item 5 (no bias (5) v potential bias (6)) 0.21 (0.13 to 0.31) 0.13-0.37 0.89 (0.86 to 0. 92) 0.72-0.95
Abdominal pain
Primary (6) v secondary care (13) 0.00-0.40 0.00-0.73 0.49-0.91 0.19-0.84
Prevalence<5% (8) v ≥5% (12) 0.00-0.50 0.00-0.73 0.29-0.84 0.19-0.91
QUADAS item 5 (no bias (10) v potential bias (8)) 0.00-0.44 0.00-0.73 0.49-0.77 0.19-0.82
QUADAS item 7 (no bias (7) v potential bias (11)) 0.00-0.49 0.00-0.73 0.29-0.82 0.19-0.91
Blood in stools
Prevalence <5% (6) v ≥5% (7) 0.25-0.86 0.38-0.71 0.31-0.88 0.36-0.72
QUADAS item 5 (no bias (5) v potential bias (6)) 0.25-0.71 0.51-0.85 0.31-0.44 0.36-0.72
QUADAS item 7 (no bias (6) v potential bias (6)) 0.44 (0.33 to 0.55) 0.25-0.71 0.72 (0.66 to 0.78) 0.37-0.88
Change in bowel habit
Primary (6) v secondary care (12) 0.10-1.00 0.06-0.86 0.55-0.93 0.28-0.94
Prevalence <5% (8) v ≥5% (10) 0.06-1.00 0.10-0.77 0.28-0.94 0.52-0.93
QUADAS item 5 (no bias (10) v potential bias (6)) 0.06-1.00 0.20-0.46 0.52-0.94 0.54-0.79
QUADAS item 7 (no bias (7) v potential bias (9)) 0.06-0.64 0.20-1.00 0.55-0.94 0.52-0.79
Guiac based faecal occult blood test†
Prevalence <5% (6) v ≥5% (8) 0.75 (0.63 to 0.84) 0.54-1.00 0.82 (0.75 to 0.87) 0.82-0.93
Diet yes (4) v no (4) 0.67 (0.53 to 0.79) 0.73-0.92 0.85 (0.76 to 0.91) 0.73-0.93
QUADAS item 5 (no bias (4) v potential bias (9)) 0.82 (0.71 to 0.90) 0.54-1.00 0.83 (0.72 to 0.91) 0.79-0.93
QUADAS item 7 (no bias (5) v potential bias (9)) 0.80 (0.69 to 0.88) 0.54-1.00 0.82 (0.75 to 0.87) 0.73-0.89
QUADAS=quality assessment of diagnostic accuracy studies.
*Ranges in case of heterogeneity; pooled estimates (95% confidence intervals) in case of homogeneity.
†Excludes study by Fijten et al34 because of inclusion criterion “rectal bleeding.”
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Fig 7 | Risk of colorectal cancer in patients with iron deficiency anaemia (positive predictive
value) versus risk in patients without (1−negative predictive value)
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combinations of symptoms improve the sensitivity at
the cost of specificity as these symptoms are common
in primary care. The two week referral guideline com-
bines symptoms, resulting in a high sensitivity (range
0.80-0.94, median 0.92) and low specificity (0.30-0.56,
0.42).
In their review of the two week referral guideline
Hamilton and Sharp6 conclude that rectal bleeding
and change in bowel habit have a high predictive
value for colorectal cancer, which is in contrast with
the conclusion of the review of Ford et al.74 In our
review only a few studies reported a significantly
higher risk for colorectal cancer amongpatients report-
ing one of these symptoms compared with those with-
out the symptom, indicating that the two week referral
guideline might provide only limited diagnostic infor-
mation. Heterogeneity in diagnostic value of a referral
guideline could be due to the inclusion of different
“tests.” Most favourable combinations of sensitivity
and specificity were found for a prediction rule consist-
ing of age, change in bowel habit, and blood in stools
(sensitivity 1.0, specificity 0.9), but a study on the exter-
nal validity of this prediction rule could not confirm
these favourable results.72 Our review shows that 12%
to 25% (median14%) of thepatients referredby the two
week referral guideline were eventually diagnosed
with colorectal cancer. Refining the current referral
system could help to improve specificity.
Blood tests
We found a low sensitivity for blood tests (haemoglo-
bin, erythrocyte sedimentation rate, white cell count)
in detecting colorectal cancer. Themedian probability
of cancer in patients with anaemia (positive predictive
value) was only slightly higher than in patients with
negative test results, indicating limited diagnostic per-
formance of this test in clinical practice when used as a
single test. This is in accordance with the NICE
guidelines.73 Despite this, they might provide a useful
adjunct to the general medical investigation, with con-
ditions such as iron deficiency anaemia warranting
further investigation.6
Faecal occult blood tests
We found relatively good results for diagnostic perfor-
mance of the faecal occult blood tests, especially for the
immunochemical based test, which showed high sensi-
tivity and reasonable specificity in most studies. The
probability of colorectal cancer is clearly higher in
patients with positive rather than negative findings on
the test. These favourable findings for the immuno-
chemical based test contrast with the NICE
guideline,73 which states that in patients with abdom-
inal symptoms, the sensitivity, specificity, and positive
predictive values of faecal occult blood tests are too low
to make these tests helpful.
We did, however, find large heterogeneity in the
results of studies on both guaiac based and immuno-
chemical based tests. Thismight be becauseof different
types of faecal occult blood tests being used in the pri-
mary studies. Furthermore, publications often lacked
information on dietary restrictions, the definition of a
positive test result (cut-off value, number of positive
samples), and number of test failures. Not providing a
dietary advice has been reported to affect the specifi-
city of guaiac based tests,13 but our review could not
confirm this. Overall, analyses both between and
Table 13 | Within study comparisons of sensitivity and specificity for various types of faecal
occult blood test (FOBT)
Sensitivity Specificity
No Sensitivity No Specificity
Guaiac based FOBT v immunochemical based FOBT
Thomas58
Guaiac based (Haemoccult, diet) 29/50 0.58 262/282 0.93
Immunochemical based (Hemeselect) 47/50 0.94 220/282 0.78
Jeanson36
Guaiac based (Haemoccult, no diet) 8/11 0.73 102/124 0.82
Immunochemical based (Hemeselect) 11/11 1.00 100/124 0.81
Immunochemical based (Hemoblot) 11/11 1.00 95/124 0.77
Smith53
Guaiac based (Haemoccult, Sensa, diet) 5/7 0.71 135/154 0.88
Immunochemical based (InSure) 7/7 1.00 124/154 0.81
Regular v self test
Pye48
Regular (Haemoccult, no info diet) 13/24 0.54 328/359 0.91
Self test (Coloscreen, no info diet) 8/24 0.33 331/353 0.94
Tate56
Regular (Haemoccult, no info diet) 12/15 0.80 230/260 0.88
Self test (E-Z Detect, no info diet) 8/22 0.36 341/382 0.89
Tate57
Regular (Fecatwin, no info diet) 14/15 0.93 229/320 0.72
Regular (Haemoccult, no info diet) 16/20 0.80 262/292 0.89
Self test (E-Z Detect, no info diet) 8/14 0.50 271/305 0.89
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Haemoccult, no information on diet (Pye 1990)
Haemoccult, no information on diet (Tate 1989)
Haemoccult, no information on diet (Tate 1990)
Haemoccult Sensa, diet (Smith 2006)
Self test Coloscreen, no information on diet (Pye 1990)
Self test E-Z Detect, no information on diet (Tate 1989)
Self test E-Z, no information on diet (Tate 1990)
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Fig 8 | Risk of colorectal cancer in patients with positive guaiac based faecal occult blood test
result (positive predictive value) versus risk in patients with negative result (1−negative
predictive value)
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within studies showed better diagnostic performance
of immunochemical based than guaiac based tests
and that guaiac based self tests seemed to perform
less well than the regular guaiac based tests.
Subgroup analyses within studies based on small
numbers seemed to indicate that immunochemical
based tests were more sensitive in detecting early
stages of cancer than guaiac based tests.53 58 As early
stages have far better prognoses this is an important
finding. One of these studies also showed that immu-
nochemical based tests were better than guaiac based
tests at detecting colorectal cancer at all sites. 58 These
results need confirmation in future, larger studies.
Strengths and weaknesses of our review
We extracted or reconstructed diagnostic data col-
lected from symptomatic patients in primary and
interface settings and excluded information from
healthy (screening studies) or highly selected diseased
controls, thereby preventing limited challenge bias.75
Furthermore, we studied awhole range of diagnostic
tools that are available to general practitioners instead
of focusing on only one or two tests.We adhered to the
most recent guidelines for conducting a diagnostic
review as described in the Cochrane Diagnostic
Reviewers’ Handbook.21 We used an extensive search
strategy, but by using a methodological filter we
might have missed several relevant publications. By
reference checking we tried to track down those pub-
lications that our search strategy might have failed to
identify. Use of a language restriction during the selec-
tion phase led to the exclusion of only 0.7% of all cita-
tions.
There were quite a few discrepancies in the phase of
abstract selection. The first reviewer used a highly sen-
sitive approach and selected all abstracts that could in
any way be relevant to the review, with the aim of not
missing any relevant papers. The second reviewer sub-
sequently considered all these pre-selected abstracts
and excluded those that clearly did not meet the elig-
ibility criteria. Anticipating poor agreement on some
items of the QUADAS list,76 77 two reviewers indepen-
dently assessed all papers for methodological quality
and reached consensus by discussing disagreements
on individual scores.
The studies of the various tests showed a high degree
of clinical heterogeneity, which limited the possibilities
for statistical pooling and strong conclusions on diag-
nostic performance. Reasons for heterogeneity include
different definitions of signs and symptoms, variation
in executions of tests (such as faecal occult blood tests),
and selection of populations based on particular symp-
toms or complaints.
In subgroup analyses we took into account the gen-
erally poor reporting of diagnostic accuracy78 by
excluding studies providing insufficient information
on the characteristic under study. Finally, we exten-
sively explored many potential sources of heterogene-
ity, including the adequacy of the reference standard.
Because of the small number of studies in the sub-
groups, we could not use multivariable meta-regres-
sion analysis, making it difficult to disentangle the
contribution of each source of heterogeneity.
Recommendations
Diagnostic tests as first line investigation in primary
care need to be valid, easy to perform, well tolerated
by patients, and sensitive, especially in case of serious
disease. Our systematic review shows that immuno-
chemical based faecal occult blood tests might prove
to be such tests. Evidence is lacking, however, for the
diagnostic performance of these tests in primary care
populations. We therefore urgently need high quality
diagnostic cohort studies enrolling consecutive
patients presenting with non-acute abdominal symp-
toms in primary care. Symptom combinations or two
week referral guidelines potentially have diagnostic
value, but the performance of the guideline could be
0 0.2 0.4 0.80.6
Positive predictive
value (PPV)
1–negative predictive
value (1–NPV)
HemeSelect (Jeanson 1994)
Hemeselect (Thomas 1992)
Hemoblot (Jeanson 1994)
iFOBT strip (Shastri 2008)
Immunohemostick (Miyoshi 2000)
Insure (Smith 2006)
Fecal HbAb (Sieg 1998)
Fecal HbHp (Seig 1999)
Fecal Hb (Levi 2007)
Fecal Hb (Sieg 1998)
Fecal Hb (Sieg 1999)
0 0.2 0.4 0.80.6
Fig 9 | Risk of colorectal cancer in patients with positive immunochemical based faecal occult
blood test result (positive predictive value) versus risk in patients with negative results
(1−negative predictive value). All studies were conducted in secondary care.
HbAb=haemoglobin-albumin complex, HbHp=haemoglobin-haptoglobin complex
Table 14 | Within study comparison of sensitivities for various tumour stages and locations
according to positive result on guaiac based or immunochemical based faecal occult blood
test
Guaiac based test Immunochemical based test
No Sensitivity No Sensitivity
Dukes’s stage
Thomas58
A 4/8 0.50 7/8 0.88
B 11/21 0.52 21/21 1.00
C 9/13 0.69 12/13 0.92
D 7/8 0.88 7/8 0.88
Smith53
A 1/3 0.33 3/3 1.00
B 1/1 1.00 1/1 1.00
C 3/3 1.00 3/3 1.00
D — — — —
Location
Thomas58
Rectum 13/25 0.52 24/25 0.96
Other left sided cancer 11/15 0.73 14/15 0.93
Right sided cancer 5/10 0.50 9/10 0.90
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improved by standardisation, clear definitions, and the
addition of important characteristics of those diag-
nosed with colorectal cancer but not fulfilling the cur-
rent guideline.
In future research, cancer location and stage of dis-
ease shouldbe an important factor in the analysis, espe-
cially as tests that are able to diagnose early stages of
colorectal cancer are important tools to reduce the bur-
den of cancer.
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